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ABSTRACT

Wang, Fa. Ph.D., Purdue University, August 2016. The Mechanism of Vitamin D
Mediated Protection from Experimental Colitis. Major Professor: Dr. James Fleet.

Inflammatory bowel disease (IBD) describes chronic and relapsing digestive system
inflammation and affects over 1.5 million people in the US. Current treatment strategies
for IBD are expensive and often lead to unsatisfactory outcomes. Therefore it is essential
to understand the mechanism of IBD progression and develop prevention strategies.
Epidemiological evidence showed that IBD risk is negatively associated with vitamin D
status. This is consistent with the clinical observation that people with vitamin D deficiency
have increased IBD severity. To establish the causal link between vitamin D status and
IBD development, our lab used dextran sulfate sodium (DSS) to induce experimental colitis
in mice which were fed either a high or low vitamin D diet. We found that low vitamin D
intake caused more severe body weight loss and spleen enlargement in mice. Since colitis
development is regulated by both colon epithelial cells and infiltrating immune cells, our
next research goal was to separate the vitamin D effect on the two cell compartments and
investigate their independent roles in the development of experimental colitis. To test the
role of vitamin D signaling in colon epithelial cells, we developed a DSS inducible, large
intestine specific transgenic mouse model, which enabled the examination of vitamin D
receptor (VDR) function in colon epithelial cells during DSS-colitis. We found that

xvi
deleting VDR in colon epithelial cells (CAC; VDR KO) caused more severe colon damage
but did not affect colon mucosa healing, immune cell activation or systemic colitis response
(i.e., body weight loss, disease activity and spleen enlargement). To test the role of VDR
in non-epithelial cells (primarily immune cells) during DSS-colitis, we used HV2; VDR
KO mouse model non-epithelial cell VDR deletion. We demonstrated that deleting VDR
from non-epithelial cells caused more robust colitis in both local and systemic levels,
indicating that VDR in non-epithelial cells plays a more important role in colitis prevention
than VDR in colon epithelial cells. We further tested the colonic cytokine profile in both
CAC; VDR KO and HV2; VDR KO mice and found delayed healing corresponding to
elevated M1 macrophage (Mɸ) activity. Therefore, we hypothesized that vitamin D can
directly regulate Mɸ phenotype during colitis. This hypothesis was supported by a series
of in vitro experiments using murine peritoneal Mɸs, which showed that 1,25(OH)2D
treatment inhibited M1 while facilitating M2 Mɸ polarization and phenotype switching.
The major finding of my thesis work is that vitamin D signaling protects against
experimental colitis in mice through the primary effect of regulating Mɸ phenotype and
the secondary effect of colon epithelial cell VDR response. Further experiments are needed
to investigate the upstream regulation of vitamin D on monocyte- Mɸ lineage response
during colitis.

1

CHAPTER 1.

LITERATURE REVIEW: THE ROLE OF VITAMIN D IN
INFLAMMATORY BOWEL DISEASE

1.1

Introduction

Inflammatory bowel disease (IBD) is a worldwide health issue and is commonly
diagnosed in western countries, such as North America, North Europe and Australia (1,
2). The term IBD describes chronic and relapsing inflammatory response in the intestine,
and can be further categorized as Crohn’s Disease (CD) and Ulcerative Colitis (UC) (3).
A recent report by the Center for Disease Control (CDC) estimated that there are 1-1.3
million people in US with IBD. The number of new diagnosed cases each year ranges
from 3.1 to 14.6 cases per 100,000 people for CD and from 2.2 to 14.3 cases per 100,000
people for UC (CDC report). The average annual cost of IBD management is over
$25000 per patient. If uncontrolled, IBD will also cause more severe health issues (e.g.
colon cancer, cardiovascular diseases, etc.) and increased death rate (4, 5). For example,
the mortality risk of CD patients is increased by up to 50% compared to healthy
population (6-8). So far, medication can only alleviate the disease symptoms to a certain
extent but not completely eliminate the disease development.
Life style factors influence human IBD risk and disease development. Since the late
20th century, IBD incidence in newly industrialized Asian countries has dramatically
increased and is currently higher than that of the Western countries (9). This increased
IBD incidence may due to Westernized lifestyle behaviors (smoking, stress, physical

2
activity etc.), environmental factors (e.g. pollution), and diet (e.g. high fat and low fiber)
(10). One of the dietary factors, vitamin D, has been proposed to protect against IBD
(10). This hypothesis has been supported by the evidence that IBD patients are often
diagnosed with vitamin D deficiency, and serum 25-hydroxyvitamin D (25(OH)D) level
is negatively correlated with CD severity (11, 12). Multiple cell types in the inflamed
intestine are potential vitamin D regulating targets, but the mechanisms have not been
fully understood. This review will first introduce the current understanding of IBD
development and management. It will then focus on the potential mechanisms of vitamin
D mediated protection against IBD through regulating immune response and colon
epithelial cell function.

1.2

Overview of IBD

1.2.1

Definition of IBD

IBD refers to chronic and relapsing inflammatory response in the gastrointestinal
tract, and it can be further categorized as CD and UC (3). IBD patients suffer from gut
inflammation that causes local and systemic symptoms, including colon ulceration,
gastrointestinal bleeding, diarrhea, anemia, abdominal pain, and weight loss among
others (13). CD and UC have different characteristics based on the disease location and
histological phenotypes. In CD patients, histological damage can be observed as skip
lesions at any location through the gastrointestinal (GI) tract. The damage often extends
to the transmural layer which will further result in fibrosis and obstruction in the late
stages of CD (14). UC, however, is mostly diagnosed in the large intestine, including the
proximal colon, distal colon and rectum (15). The damage and inflammation is often
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limited to mucosa without the involvement of deeper layers of the colon wall. IBD
significantly reduces the quality of life for patients and increases the risk of developing
other diseases, such as colon cancer and heart failure (4, 5). Current strategies for IBD
management are expensive and the outcomes are not satisfied (16). Therefore, it is of
urgent importance to understand the pathogenesis of IBD and develop novel prevention
and treatment strategies against the disease.
1.2.2

IBD is a complex disease with multiple risk factors

IBD is a complex disease resulted from the interaction with multiple factors,
including genetics, life-style, infection, and immune system disturbance (13). All of these
factors, individually or combined, may affect disease initiation, development, recovery
and relapse.
Genetics and IBD. Individuals with IBD family history have 8-10 times higher risk
to develop this disease, which suggests the heritable potential of IBD (17). Epidemiology
studies also showed that genetic background was associated with IBD risk. For example,
individuals of European descent have higher risk of developing IBD (18), even though
this may also be due to environmental influences and other confounding factors. One of
the earliest genes identified to have a direct impact on CD susceptibility is Nucleotidebinding oligomerization domain-containing protein 2 (NOD2), which encodes a plasma
pathogen recognition receptor involved in innate immune response regulation and antimicrobial function (19). Individuals with NOD2 gene mutation also have increased IBD
risk. Starting from the early 2000’s, genome-wide association studies (GWAS) have been
conducted across populations, and until 2013, numerous candidate genes within 163 loci
have been linked to IBD (20). The concordance rates of IBD in twins have been
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analyzed to estimate the contribution of genetic factors to IBD. The concordance rates of
monozygotic and dizygotic twins in CD (30.3% and 3.6%) are higher than those in UC
(15.4% and 3.9%) (21). This indicates that genetic factors contribute more to CD
development than to UC. In addition, it also suggests that factors other than genetics
induce disease development (22).
Lifestyle and IBD. IBD incidence has increased with industrialization in developing
countries, indicating life-style factors may influence disease development. As early as the
1950s, IBD was mostly recognized and diagnosed in North American and North Europe,
and so far the IBD prevalence is still the highest in developed countries (1, 2).
Interestingly, IBD incidence was significantly increased in newly industrialized countries
starting from the late 20th century (23). Because of this, Westernized life-styles, including
smoking, urban setting, obesity, stress and diet, have been associated to increased IBD
risk (24). Among those, dietary factors have attracted the most attention. Observation
studies showed that people having high fat diet were more likely to develop IBD,
whereas those consuming a diet containing high fiber, fruit and vegetables had lower IBD
risk (25). More specifically, n-6 polyunsaturated fatty acids (PUFA) rich meat, such as
red meat and cooking oils, has been linked to increased UC risk, whereas n-3 PUFA is
healthier (26). Vitamins and minerals are also associated with IBD pathogenesis. For
example, dietary vitamin D has been proposed to have protective effects against IBD
through its immune regulation function (27). IBD patients are often diagnosed with
vitamin D deficiency, especially those with active and severe IBD symptoms (28). From
the treatment aspect, vitamin D supplementation raised up vitamin D status in IBD
patients and meanwhile improved IBD disease outcomes in clinical trials (28, 29).
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Infection, gut flora and IBD. The human gut contains as many as 1014 bacteria
cells, and some of them are associated with gut homeostasis and IBD development (30,
31). For example, salmonella and campylobacter infections have been associated with
higher risk of IBD (32). Paratuberculosis is also suggested to induce CD but the results
among studies are not consistent (33, 34). In contrast, parasite infection (e.g. Helminth)
protects against IBD, and the proposed mechanism is through parasite induced nonclassical macrophage (Mɸ) polarization and activation (35). Not only pathogens but also
unbalanced commensal bacteria in the gut affect IBD risk. Gut flora interact with
multiple environmental factors, which may alter the composition or density of gut
microbiota (36). It has been observed that IBD patients have lower overall gut bacteria
diversity. However, certain intestinal bacteria species, such as adherent-invasive
Escherichia coli, are overpopulated in CD patients compared to healthy individuals (37).
In contrast, Firmicutes, as a potential beneficial species protecting against IBD, is less
populated in the intestine of IBD patients (38). Because of the complexity of gut flora
populations and their interactions with the host mucosa immune system, gene-sequencing
technologies and bioinformatics tools are widely used to characterize gut microbiota
composition change through IBD development (39). Further investigation needs to be
done to identify whether such bacterial population alterations are causal factors to induce
IBD.
Immune system and IBD. IBD is primarily characterized by immune cell overactivation induced by commensal bacteria and self-antigens in GI tract, making it an
autoimmune disease (40). For example, intestine Mɸs may have lost tolerance to
commensal bacteria and thus produce high level of TNF-α (41). This can further increase
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Mɸ and T cell gut infiltration and thus induce a more robust immune response in the gut
(40). Moreover, the pro-inflammatory response is not limited to local tissue but is also
seen systemically. For example, IBD patients often have elevated serum TNF-α
concentration compared to healthy population (42). The pathogenesis of two IBD subtypes are different regarding the dominant adaptive immune response. CD is correlated
with an increase in Th1 and Th17 response, while UC is predominantly associated with
elevated Th2 response (43).
1.2.3

The mechanisms of IBD development

The etiology and pathogenesis of IBD have been investigated for many years and
current evidence suggests that mucosa microbiota alteration, mucosa barrier dysfunction
and abnormal mucosa immune response promote IBD development (44). This process is
also influenced by genetic alteration and environmental factors (44, 45).
1.2.3.1 Mucosa barrier function and IBD
Intestinal epithelium functions as the first barrier of host defense, where it prevents
invasive pathogens from entering the host tissue. It contains different mucosa
components and intestinal cells with distinctive roles. The first protective layer is a
physical mucus layer which prevents the direct colonization of gut microbiota on mucosa.
Goblet cells are the main resource of mucus protein (46). IBD patients often have
reduced goblet cell count or defected mucus production (47). The protective role of
mucus has been further demonstrated in animal studies by showing that Muc-2 deficient
mice (which lack mucus production) developed spontaneous experimental colitis in mice,
but Muc-2 wild type ones did not (48). Within the intestine mucus layer, anti-microbial
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peptide (AMP) produced by Paneth cells is another important compound to prevent
bacteria infiltration (49). AMP is part of the innate immune mediators which kills a broad
spectrum of bacteria in the intestinal lumen (50). Reduced AMP level has been seen in
the intestinal mucus of IBD patients, which suggests the potential protective effect of
AMP against IBD (51).
Intestinal epithelial cells connect to one another by forming tight junctions (TJ)
which protect the gut epithelial monolayer integrity against luminal antigen infiltration
(52). IBD patients often have “leaky gut”, which demonstrates increased gut permeability
with loosened cell-cell connection. This leaking phenotype may be caused by reduced TJ
protein levels (e.g. ZO-1 and Claudin-2) or altered protein locations (e.g. E-cadherin),
both of which are associated with IBD development (53). The current understanding of
the initiating factors to mucosa barrier impairment remains unclear (54). Recent evidence
has shown that pro-inflammatory cytokines (e.g. TNF-α) can increase gut permeability by
altering TJ and inducing epithelial cell apoptosis, further initiating local immune response
(55). Moreover, CD patients responding to anti-TNF-α treatment often had an
improvement in gut epithelium integrity and permeability (56). This data indicates the
importance of altered TJ functions on IBD initiation.
In addition to forming a physical protective barrier, intestinal epithelial cells are also
involved in innate immune activity. Many epithelial cells have pattern recognition
receptors expressed on their apical surface (e.g. TLR4), basal surface (e.g. TLR9) and
cytoplasm (e.g. NOD2) (57). Toll-like receptor (TLR) expressed on epithelial cell apical
surface induces immune tolerance. Under normal conditions, commensal bacteria will be
recognized by TLR without inducing a pro-inflammatory response (58). As bacteria
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infiltrate into the cell or reach the lamina propria, NOD2 in the cytoplasm and TLR on
the basal side will recognize the antigens and initiate the innate immune response. NOD2
or TLR signaling will further activate the epithelial cell NF-κB signaling pathway and the
invading foreign antigens will be cleared out (58).
1.2.3.2 Gut microflora and IBD
CD and UC frequently develop in the distal ileum and colon where large amounts of
bacteria are located. This suggests that gut microbiota may be associated with IBD
development (59). Studies with germ-free animals provid evidence that gut bacteria may
be a causal effect on IBD. Germ-free mice failed to develop spontaneous colitis (60), and
instead develop milder dextran sulfate sodium (DSS)-induced colitis compared to mice
raised under normal conditions (61). In general, two potential mechanisms have been
proposed to explain IBD initiation from gut microflora. One is persistent infection caused
by gut pathogens, and the other is dysbiosis. The latter describes the shifted balance of
beneficial and detrimental bacteria populations in the gut.
With overall high bacteria density in IBD patients’ gut lumen, some potential
pathogens are overpopulated which may contribute to IBD initiation. For example,
Adherent-Invasive E. coli. (AIEC), also known as CD-associated E. coli, is highly
populated in the ileum of 22% CD patients (37). The significance of AIEC pathogenic
function was further strengthened in animal studies that transfection of AIEC in mice was
sufficient to induce gut inflammation (62). AIEC has an extremely high capacity to
colonize to mucosa, infect intestinal epithelial cells and initiate Mɸs mediated proinflammatory response (63). AIEC also is also present in relatively lower amounts among
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healthy populations than in CD patients, suggesting that AIEC may be a conditional
pathogen and more likely to cause disease in sensitive individuals (64).
Dysbiosis describes a condition of luminal microbial imbalance, which is another
possible cause of IBD. By analyzing washed colonic biopsies from 305 IBD patients and
40 healthy individuals, Swidsinski et al. demonstrated that the overall density of mucosa
bacteria in IBD patients was significantly increased compared to healthy controls (59).
They also reported that the bacteria density in IBD patients was positively related with
disease severity. Frank et al. used sensitive molecular-based sequencing analysis and
further characterized the microbiota shift in IBD patients (65). Firmicutes (~60%),
Bacteroidetes (~30%), Proteobacteria and Actinobacteria phyla are four major microbiota
populations in a healthy gut. In IBD patients, a significant depletion of Firmicutes and
Bacteroidetes was observed, whereas increased numbers of Proteobacteria and
Actinobacteria were found. This evidence suggests that maintaining luminal bacteria
balance may protect against human IBD.
1.2.3.3 Immune system and IBD
IBD and innate immune response. Mononuclear phagocytes, including Mɸs and
dendritic cells (DC), are the most abundant cell types in the innate immune system and
have central roles in maintaining intestinal mucosa homeostasis and in regulating
immune response. Mucosa Mɸs have high phagocytic activity but do not migrate to
lymph nodes, whereas DCs migrate to lymph nodes and prime naïve T cells. In intestine
steady state, mucosa Mɸ is responsible for detecting and clearing out luminal bacteria.
Unlike inflammatory Mɸs, mucosa Mɸs constantly produce high levels of IL-10 and low
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levels of TNF-α, and their interaction with commensal bacteria in steady state does not
induce pro-inflammatory cytokine production. Unlike in healthy individuals, Mɸs in CD
and UC patients’ mucosa may have lost their immune tolerance to luminal bacteria. The
number of pro-inflammatory Mɸs (CD14+) is often increased in IBD patients (66),
leading to increased levels of Mɸ produced mediators in the gut, such as TNF-α, IL-12,
IL-1β, and reactive oxygen and nitrogen species. Mɸs in inflamed gut are derived from
blood monocytes and commonly classified into two categories, M1 and M2. This
classification is based on their cell surface markers and biological functions (67, 68). M1
Mɸs are classically activated Mɸs induced by LPS and IFN-γ. They express high levels
of major histocompatibility complex (MHC) II, produce large amounts of proinflammatory mediators (i.e. ROS, TNF-α, etc), and function through defending against
mucosa infection and activating adaptive T cell response (69). On the other hand, M2
Mɸs are non-classically activated Mɸs polarized by IL-4 and IL-13(70). They express
high levels of CD206 on cell surface and produce higher levels of growth factors (e.g
TGF-β) and anti-inflammatory cytokines (e.g. IL-10). These M2 produced immune
regulators facilitate mucosal healing and suppress the local immune response (71). M1
and M2 phenotypes are interchangeable and the balance between the two is highly
relevant to experimental colitis severity (72-74). An increased M1 to M2 ratio has been
observed during colitis progression and a reduced ratio was seen during recovery (73,
74). This implys that M2 Mɸ is important for mucosa healing by producing antinflammatory cytokines (e.g. IL-10) and growth factors (e.g. TGF-β). Delayed mucosa
healing was observed in Mɸ specific TGF-βRII signaling deletion (CD68-dnTGFβRII)
mice after DSS treatment (75). Moreover, adoptive peritoneal transfer of M2 Mɸ
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eliminated Dinitrobenzene sulfonic acid (DNBS) induced experimental colitis severity in
mice (76). This suggests the important role of M2 Mɸs on IBD recovery. In addition,
clinical observation show that IBD patients who respond to anti-TNF-α treatment also
have increased CD206+ Mɸ (M2) number in intestine (77).
Similar to Mɸs, DCs also have two sub populations responsible for immune
stimulating or immune regulating effects (78). Most of the work on DCs has been done in
mice even though the DC population in mice and humans may not be identical. Mucosa
DCs in mice express cell surface marker CD103 and CD11b (78). Under healthy
conditions, mucosa DCs are hyporesponsive to commensal bacteria, and they are
therefore considered as tolerogenic DCs. These cells produce IL-10 and functions by
activating regulatory T cells and suppressing adaptive immune response. DCs loss of
immune tolerance has been linked to increased risk of IBD (79, 80).
IBD and adaptive immune response. IBD patients also experience disrupted
adaptive immune response (T and B cell differentiation and activation) in the intestine,
which is directly regulated by innate immune cells. (81, 82). Early studies mainly focused
on shifted Th1 and Th2 balance in IBD. Th1 lymphocytes, which are activated by M1
Mɸ and DC, are over-activated in patients with active CD. Activated Th1 cells produce
high levels of TNF-α, IL-12 and IFN-γ which further activate Mɸs and induce cytotoxic
effects (82). In contrast, UC patients are often diagnosed with Th2 cell overpopulation.
Activated Th2 cells produce high levels of IL-4, IL-5, IL-13 and TGF-β, and further
activate B cell induced humoral response (83). The antibody-dependent cell-mediated
cytotoxicity (ADCC) induced by B cells may further cause prolonged tissue damage in
UC.
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An imbalance in the response of two more recently discovered cell types, Th17 and
Treg, also contributes to IBD development (84). Both cell types are differentiated from
Th0 and commonly regulated by TGF-β (85). In pro-inflammatory environment (high
levels of IL-6 or IL-21), TGF-β favors the differentiation of Th17, while in steady state or
anti-inflammatory environment (high levels of IL-10), it promotes Treg differentiation
(85). Th17 is activated by IL-23, which is produced by activated M1 Mɸs and NK cells.
Increased Th17 cell infiltration and Th17 related cytokines (e.g. IL-23 and IL-17A) have
been observed in the inflamed mucosa of both CD and UC patients (86). This suggests
that Th17 cell response may be associated with IBD pathogenesis. Indeed, GWAS studies
showed strong association between Th17 cell related genes (e.g. IL-23R) and human IBD
(87). However, animal studies created controversy regarding the role of Th17 cells in
colitis. IL-17A gene deletion increased the disease severity of DSS-induced experimental
colitis (88), whereas IL-17R knockout significantly protected against 2,4,6trinitrobenzenesulfonic acid (TNBS)-induced colitis (89). These results suggest that Th17
regulates IBD development in a much more complex fashion. As mentioned before, Th17
and Treg balance is important for gut homeostasis and mucosa response to environmental
insults. Tregs play an important role in immune tolerance and suppression, which may
reduce the risk of auto-immune response (90). Since IBD has long been considered as an
auto-immune disease, the regulation of Treg on IBD has been extensively studied. The
potential clinical relevance of Treg and IBD has recently been reviewed (91).
B cell mediated mucosa humoral immune response has also been associated with
IBD pathogenesis. Increased numbers of infiltrating B cells (including plasma cells) were
observed in the intestine of both CD and UC patients, and the phenotype of
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immunoglobulin produced by plasma cells skewed from IgA to IgG in IBD (92-94). In
normal mucosa, IgA is the main immunoglobulin subtype which keeps the gut
homeostasis from three aspects. First, IgA complex binds invading pathogens and
effluxes them to the lumen through pIgR (95). Second, IgA potentially suppresses
neutrophils and Mɸs recruitment to the gut (96). Third, it reduces monocytes and Mɸs
producing TNF-α (97). In acute infection, IgG is beneficial because it is a much more
efficient form than IgA to enhance Mɸ phagocytic property and remove invading
pathogens. However, IBD patients have sustained high IgG levels in the gut, which
become deleterious due to IgG induced chronic inflammation and potential auto-immune
response (98, 99). In CD, increased IgG is predominantly anti-E Coli, whereas in UC, the
IgGs are mainly targeting colonic epithelial cells. In addition, overproduction of IgG can
over-activate complement system and ADCC effect which may cause further tissue
damage and delayed mucosa healing (93, 100). B cell mediated immune response in IBD
is a fine and complex regulation and further research is required to explore the
mechanisms.
1.2.3.4 Mucosal healing and IBD
Mucosa healing, which describes epithelium integrity and functionality recovery, has
been merged into a crucial IBD therapeutic goal (101, 102). When steroid medicine was
first used to treat UC, the clinicians observed that the treatment was more favorable in the
patients who had both clinical and endoscopic remission compared to those who were
clinically recovered only (103). Rapid mucosa healing was later observed in CD patients
who responded to anti-TNF-α treatment (104). Collectively, these observations raised
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research interest in the mucosa healing process which could influence the natural course
of both UC and CD. Clinical mucosa healing is defined as the resolution of ulcer and
erosion in IBD under colonoscopy (105). Mechanistically, mucosa healing is a complex
biological procedure that depends on the communication between intestinal epithelial
cells, immune cells and stroma cells (106).
Mucosa healing is a multi-step process, including epithelial restitution, proliferation
and differentiation. Epithelial restitution is the earliest healing response which happens
only minutes after mucosa surface injury (107). The epithelial cells residing adjacent to
the wound depolarize, quickly migrate, and seal the open ulcer. Restitution is tightly
regulated by growth factors and cytokines (108, 109). For example, TGF-α is a growth
factor that induces epithelial cell migration by activating ERK-MAPK signaling pathway.
Right after restitution, epithelial cells undergo rapid proliferation and crypt fission,
resulting in increased cell and crypt numbers in the ulcer bed. Epithelial cell proliferation
during healing is dependent on the activation of NF-κb and STAT3 signaling pathways.
The activation is favored by certain local cytokine induction, such as IL-6 and IL-22
(110). Some other cytokines, such as TNF-α, would induce epithelial cell apoptosis
instead, thereby delaying the healing process (111). The TLR family (such as TLR2,
TLR4 and TLR9) and downstream signaling pathways may be beneficial during wound
healing. For example, TLR2 expressed on colon epithelial cells can be activated by
bacterial antigens, which will then induce goblet cells producing Trefoil factor 3 (TFF3)
(112). TFF3 is an apoptotic compound and its deficiency is associated with delayed
mucosa healing in colitis. This may be due to reduced epithelial proliferation or stem cell
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survival rate (113). Following stem cell mediated colonocytes differentiation, the crypt
structure and function will be recovered.
1.2.4

Current management and treatment strategies on IBD

Multiple treatment strategies have been developed to induce the remission of IBD,
including modulating inflammatory mediators, lymphocytes migration and luminal
bacteria population. One of the earliest anti-inflammatory medicines for IBD treatment is
corticosteroids, which are effective in both UC and CD patients (114). Corticosteroids
work quickly, are easy to use, and are not as expensive as other medicines. However,
these drugs are only effective in a short term, and thus do not satisfy the role of sustaining
IBD remission (114). Moreover, there are also toxicity concerns about this drug.
Corticosteroids are a universal anti-inflammatory medicine that cause overall immune
suppression, which increases the infection risk of IBD patients (115, 116). Therefore,
corticosteroids need to be applied with other medicines to improve the treatment
outcomes in IBD.
Anti-TNF-α antibody is also widely used to clinically treat IBD. The most common
drugs are infliximab and adalimumab (117, 118). Both are effective for treating acute
CD, but infliximab is more effective than adalimumab for treating UC (117, 118). The
advantage of anti-TNF-α treatment is that the drug only targets one pathogenesis cytokine
instead of the overall immune response, and as a result no side effects of anti-TNF-α
treatment have been reported to increase infection or cancer risk (119). By combining
infliximab and thiopurines, the short duration of remission is significantly improved
compared to using infliximab alone (120, 121). The longer duration of infliximab may be
because of its role in improving wound healing in the gut. These advantages expand the
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usage of this drug in the clinic, but there are also limitations. First, the anti-TNF-α
antibody is usually expensive (122). Second, about one third of IBD patients do not
respond to this treatment, and even those who initially respond to it will build up
tolerance and lose the treatment effect (123). This suggests that diagnosis and treatment
should be personalized, and that alternative strategies are needed for IBD treatment.
Vedolizumab is a monoclonal antibody that specifically prevents lymphocytes
adhesion and migration to the gut. It functions through blocking α4β7 integrin and ligand
binding. The major advantage of this drug is that it is gut specific and the systemic
immune toxicity is significantly reduced. Vedolizumab is a new IBD treatment medicine
approved by the FDA in 2014, and has been used as an alternative treatment option for
those that do not respond to anti-TNF-α treatment (124). Clinical studies showed that
treatment of Vedolizumab to UC and CD twice (at week 0 and week 2) significantly
improved remission by week 6 (125). Long term usage of the drug for a year resulted in
significant IBD remission compared to placebo controls (126). A new drug specifically
targeting β7 is being developed, with the goal of improving the drug specificity in gut
mucosa only (127).
Since gut microbiota play a non-negligible role in IBD development, antibiotics and
probiotics are used to control the total number and balance of bacteria. Antibiotics are
used to treat active stage IBD especially when bacteria translocation is observed (128). A
meta-analysis concluded the beneficial effect of antibiotics on IBD treatment by
comparing 10 clinical trials using different antibiotics compounds in various populations
with either active or quiescent IBD (129). Probiotics have also been used under
inconsistent clinical conditions and thus the evidence of its efficacy on IBD treatment is
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not as strong. It works effectively for UC treatment in some circumstances but has no
beneficial effect on managing CD (130).

1.3

Overview of vitamin D

Vitamin D is a fat soluble pre-hormone traditionally known to regulate calcium
homeostasis and maintain bone health. Vitamin D has two main forms named vitamin D2
and vitamin D3 (131). Vitamin D2 is primarily found in plants, while vitamin D3 is the
dominant form in oil rich animal resource diet. Vitamin D3 can also be synthesized in
skin from 7-dehyrocholesterol under UV exposure (132). Vitamin D binds to vitamin D
binding proteins and circulates in the blood, requiring two conversion steps to become
active. First, vitamin D circulates to the liver and is converted to 25(OH)D by the enzyme
25 hydroxylase (133). 25(OH)D is a stable form of vitamin D, whose serum
concentration is used as the biomarker to evaluate an individual’s vitamin D status. The
second step is to convert 25(OH)D to its active form, 1,25 dihydroxyvitamin D
(1,25(OH)2D) by 1α-hydroxylase (CYP27B1) (134). This enzyme is mainly present in
kidney tubular epithelial cells, and also in extra renal tissues at a relatively low level
(135). 24-hydroxylase (CYP24A1) is the enzyme that can convert excess levels of
25(OH)D and 1,25(OH)2D in target tissue to their inactive forms, 24,25
dihydroxyvitamin D and 25 hydroxyvitamin D-26,23-lactone, and then to the water
soluble form calcitroic acid to be excreted via urine (134).
The United States Institute of Medicine (IOM) defines vitamin D deficiency as
serum 25(OH)D level below 30 nmol/L (12 ng/ml), and considers the level of 50 nmol/L
(20 ng/ml) to be adequate (136). To reach adequate serum 25(OH)D level, the
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Recommended Daily Allowance of Vitamin D is 600 IU for general population between
age 1-70. However, this definition of vitamin D deficiency has been challenged by the
United States Endocrine Society’s Clinical Practice Guideline, which states that serum
25(OH)D level of 75 nmol/L (30 ng/ml) is the cut-off for adequacy (132). Based on the
fact that more than half of the US population does not reach adequate vitamin D status,
the recommended vitamin D intake should be 1500-2000 IU per day (132).
1,25(OH)2D as an active hormone, binds with vitamin D receptor (VDR) and
regulates gene transcription. VDR is expressed in multiple tissues, including two cell
populations that this review is focused on, intestine/colon epithelial cells and immune
cells. When VDR binds with its ligand 1,25(OH)2D in the cytoplasm, it further
heterodimerizes with retinoid X receptor (RXR) and translocates to the nucleus. VDRRXR dimer will bind to the vitamin D response element (VDRE) in the regulatory region
of its target genes to enhance or inhibit transcriptional events (137).

1.4

Vitamin D and IBD in human and rodent models

Growing epidemiological evidence showed that the prevalence of vitamin D
deficiency is associated with increased IBD risk, including both CD and UC. The
potential causal effect of low vitamin D status and IBD development is partially
demonstrated in clinical trials and further supported by animal studies.
1.4.1 Vitamin D and IBD epidemiology
Worldwide epidemiological observation has shown that people living at high
latitudes or being exposed to limited sunlight have increased risk of IBD (138, 139).
Specifically, IBD prevalence has been observed to follow this geographic distribution in
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Northern Europe and North America (140). For example, a large population based
observation study showed that the CD and UC incidence significantly increased in those
who lived farther way from the equator in North America (141). In Europe, when those
who originally lived near the equator migrated to countries in the north, the risk of UC
and CD also increased (142). Since the majority of vitamin D can be synthesized from
skin under sunlight exposure, the hypothesis is that low vitamin D status is associated
with high IBD risk. Indeed, vitamin D deficiency is often diagnosed among IBD patients
and with a seasonal pattern (143). For example, data showed that 18-50% of IBD patients
have serum 25(OH)D levels lower than 20 ng/ml at the end of summer, whereas this
deficiency can be seen in 50-68% of IBD patients in late winter (144). Low vitamin D
status in winter also correlates with the highest IBD incidence in early spring throughout
the year (145, 146). In addition, vitamin D status is also negatively related with IBD
severity and outcomes. Data from a cross-sectional study showed that Crohn’s Disease
Activity Index (CDAI) is lower in those patients with higher serum 25(OH)D levels (12),
while patients with lower 25(OH)D levels had greater IBD disease activity (147). In
addition, IBD risk has also been associated with VDR polymorphisms, suggesting that
vitamin D signaling is a determinant factor of human IBD development (148-150).
1.4.2

Vitamin D supplementation and IBD: clinical trials

As described above, observation studies showed that vitamin D status is negatively
correlated with IBD severity and outcomes, and hence clinical trials are necessary to test
the role of vitamin D supplementation on IBD treatment. So far, no clinical trial has been
done to test the effect of vitamin D on ulcerative colitis, while three clinical studies have
been done test CD patients’ disease severity with vitamin D supplementation.
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The first open label trial included 35 patients with CD, treated with either 0.25 μg
1,25(OH)2D or 1000 IU 25(OH)D. CD patients with 1,25(OH)2D supplementation but not
25(OH)D had significantly reduced CDAI and serum C-reactive protein levels in the
short term (151). Jørgensen et al. reported the first multicenter, randomized, double-blind
clinical trial to evaluate the effect of vitamin D supplementation on CD therapy and
disease remission. 108 CD patients were recruited and given either 1200 IU/day vitamin
D3 or placebo, and followed up for 12 months. 3 months vitamin D3 supplementation
significantly increased serum 25(OH)D status, and 12 months treatment reduced the
disease relapse rate (p=0.06) (29). In another open label trial, 18 CD patients with low to
moderate CDAI were recruited and given up to 5000 IU Vitamin D3 per day for 24
weeks. Vitamin D3 supplementation with the reported dose did not induce any adverse
effect or toxicity, and significantly increased serum 25(OH)D level and reduced CDAI
score (152).
1.4.3

Vitamin D and mouse models of IBD

Rodent models have been used to understand the potential mechanisms of vitamin D
mediated protection from IBD. Mouse IBD models are mostly used, which include
chemical induced models (e.g. DSS and TNBS), bacteria induced infection models, T cell
transfer models, and spontaneous IBD models (e.g. IL-10 knockout (KO)) (153). Vitamin
D mediated protection against experimental colitis was tested by 1) feeding mice diets
with sufficient and deficient vitamin D content, 2) applying 1,25(OH)2D or its analogs as
colitis treatment strategy, and 3) using global VDR KO, conditional VDR KO and VDR
transgenic models to block or recover vitamin D induced transcriptional regulation (154156). So far, multiple evidence has shown that vitamin D is a protective factor against
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experimental colitis, and that the protection is mediated through regulating the gut barrier
function, immune function and gut microbiota population.
Intestinal mucosa, containing mainly intestinal epithelial cells and lamina propria
immune cells, is the biological barrier of the digestive system. Mucosa epithelial damage
and chronic inflammation cause GI tract dysfunction and systemic symptoms (157).
Vitamin D has been proposed to have protective roles in maintaining gut barrier integrity.
As early as 2008, Kong et al. showed that VDR KO mice developed more severe colon
ulceration after DSS-induced colitis. These mice also had reduced transepithelial
electrical resistance (TER) compared to controls, indicating increased gut barrier
permeability (158). In C. Rodentium induced mouse colitis model, low vitamin D intake
resulted in more severe bacteria infiltration in cecum and secondary lymphoid tissues
(159). Intragastric delivery of 1,25(OH)2D rapidly recovered DSS-induced colon damage,
paracellular permeability and bacteria translocation, suggesting that the vitamin Dmediated mucosa barrier protection was through colon epithelial cells (160). To further
specify the role of VDR in intestinal epithelial cells, Liu et al. used the villin-human
VDR transgenic model and found that global VDR deletion induced severe gut leaking in
TNBS induced colitis can be corrected when intestinal VDR was recovered (161).
Vitamin D regulates gut permeability by upregulating TJ gene expression levels (160,
162), maintaining appropriate TJ protein locations (163), and inhibiting colon epithelial
cell apoptosis (164-166). Details will be discussed in the later section of this review.
Vitamin D also protects Paneth cell survival, differentiation and its anti-microbial
function (167). Intestine specific VDR KO mice were more susceptible to DSS-induced
colitis and developed disordered, depleted and diffused Paneth cells during DSS
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treatment. Meanwhile, reduced ATG16L1 expression level in Paneth cells of intestine
VDR KO mice was observed, suggesting impaired autophagy function of the cells (167).
Anti-microbial gene Ang4 was also shown to be a potential Vitamin D regulating target
because mice fed low vitamin D diet had reduced Ang4 mRNA and protein levels after
DSS treatment (168).
Vitamin D functions as an adaptive immune modulator during experimental colitis
and thereby protects against disease development. VDR KO mice developed more severe
colitis induced by DSS compared to wild type controls, and symptoms included elevated
intestine inflammation and pro-inflammatory cytokine production in colonic tissue (154).
This suggests that increased sensitivity of VDR KO mice to DSS is potentially through
altered immune response. Previous research mainly focused on the impact of vitamin D
signaling on T cell response. First, vitamin D alleviates experimental colitis by
suppressing Th1 while inducing Th2 cell response (155, 169-171). For example,
1,25(OH)2D oral treatment significantly increased anti-inflammatory cytokine IL-10 (Th2
and Treg cytokine) levels while decreased pro-inflammatory cytokine IFN-γ (Th1
cytokine) in DSS-induced colitis model (154). A similar effect was also found in T-cell
mediated TNBS-induced colitis model, that 1,25(OH)2D analog calcitriol or ZK156979
treated mice had reduced Th1 and induced Th2 and Treg response in the colon (155,
171). IL-10 is a Th2/Treg produced anti-inflammatory cytokine which inhibits colitis
development, while deletion of IL-10 gene induces spontaneous colitis in mice. VDR/IL10 double KO had increased small intestine and colon structure disruption compared to
IL-10 single gene deletion, together with induced IL-1β, IL-2, IFN-γ and TNF-α
concentration in local gut (172). This observation is consistent with an early report that
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1,25(OH)2D supplement reduced small intestine inflammation and overall disease activity
in IL-10 KO mice (173). Second, vitamin D also regulates Th17 cell response in colitis.
IL-17 is significantly increased in VDR KO IBD mice with increased severity of tissue
damage (174). This is consistent with increased Th17 cell numbers in damaged mucosa
compared to controls (174). In the RAG KO model with depleted T and B cells, VDR KO
T cell adoptive transfer increased colitis severity with increased IL-17 producing cell
numbers both in the colon and in circulation (174). This suggests that VDR signaling is
important for regulating Th17 cell differentiation and activation. In addition, VDR KO
mice had reduced intraepithelial lymphocytes CD8 αα+ T cell numbers in gut mucosa,
which has an anti-bacterial effect in the gut (175). This may partially explain the
increased sensitivity of VDR KO mice to salmonella induced colitis (176).
Gut bacteria are also associated with colitis pathogenesis, and vitamin D is proposed
to inhibit colitis development by maintaining the balance of gut microbiota populations.
Data showed that Cyp27b1 KO and VDR KO mice developed more severe DSS-induced
colitis, which was associated with increased detrimental bacteria species (Bacteroidetes
and Proteobacteria phyla) and reduced beneficial bacteria species (Firmicutes and
Deferribacteres phyla) in the feces (162). Similarly, the altered gut microbiota were also
observed in vitamin D deficiency mice which were more susceptible to developing
experimental colitis (163, 177)(159). This regulation on microbiota is partially through
vitamin D signaling in intestine epithelial cells. Inactivating VDR in intestinal epithelial
cells is sufficient to alter gut microbiota populations, such as reducing the number of
Butyrate producing bacteria, Butyrivibrio (167). Probiotics can also regulate VDR
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expression in intestinal epithelial cells; they then induce epithelial cell anti-microbial
activity and suppress pathogen induced colitis (178).

1.5

Vitamin D and immune response

The earliest evidence of vitamin D’s immune regulation function was reviewed
through its usage on treating mycobacterial diseases (e.g. tuberculosis (TB)) 70 years
ago, even though the mechanism was not clear at that time (179, 180). For a long time,
the importance of vitamin D and its effect on the immune system was widely recognized
because VDR was found in multiple immune cells types. Active form of vitamin D,
1,25(OH)2D was found to bind to transcription factor VDR in T cells, B cells,
monocytes/Mɸs, DCs and neutrophils, suggesting that immune cells may directly respond
to circulating 1,25(OH)2D (181-185). Meanwhile, other studies discovered that human
Mɸs also express CYP27B1, which encodes the enzyme to convert 25(OH)D to its active
form 1,25(OH)2D (186). This highlights the potential that 1,25(OH)2D can regulate
immune cell function in an autocrine manner. The following session, further discusses the
molecular mechanisms of vitamin D mediated innate and adaptive immune response
regulation.
1.5.1

Vitamin D and innate immune cells

Two major types of innate immune cells, Mɸ and DCs, are both vitamin D
responding cells and their biology is tightly associated with IBD. Mechanistically,
vitamin D regulates monocyte /Mɸ anti-microbial effects, proliferation and
differentiation, migration and immune regulation. Vitamin D also influences DC antigen
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presentation and maturation. Details of these regulation mechanisms will be discussed
below.
Vitamin D and its anti-microbial effects on monocyte/Mɸ. Vitamin D’s antimicrobial effects were first observed from its usage in treating TB, and then emphasized
in a large-scale in-silico and microarray study that two anti-bacteria genes, cathelcidin
(cAMP) and β-defensin 2 (DEFB4) were upregulated by 1,25(OH)2D (187). DR3
consensus VDREs were found in the promoter regions of both genes, suggesting that the
two genes are direct vitamin D regulating targets (187). However, it has later been proved
that only cAMP can be transcriptionally regulated by 1,25(OH)2D in monocytes, whereas
DEFB4 expression can only be indirectly regulated by VDR when pro-inflammatory
transcription factor NF-κb is co-activated (187). It was later discovered that NOD2 gene
transcription was directly regulated by vitamin D, which resulted in NF-κb activation and
increased DEFB4 expression (188). When monocytes were co-treated with 1,25(OH)2D
and NOD2 ligand (muramyl dipeptide), NF-κb dependent DEFB4 enhancement was
observed (188). Genetic variants of NOD2 are associated with increased CD risk (189).
For example, G908R, R702W and L1007 frameshift deletion of NOD2 have been linked
to the development of CD, which is due to insufficient activation of bacterial killing
capacity (19). Therefore, vitamin D has anti-microbial effects and protects against human
IBD.
Vitamin D and monocyte/Mɸ proliferation and differentiation. In addition to its
anti-microbial effect, 1,25(OH)2D also suppresses human PBMC proliferation. Sito et al.
showed that 1,25(OH)2D or its analogues (EB 1089, KH 1060) significantly reduced the
proliferation of PBMCs in CD patients (190). Vitamin D also induces monocyte-Mɸ cell
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lineage differentiation. Early studies showed that 1,25(OH)2D alone induced the
differentiation of bone marrow derived Mɸ (BMDM) in both mice and humans based on
observation of morphology change (191). In the presence of M-CSF or L929 culture
medium, 1,25(OH)2D co-treatment further induced mouse BMDM cell surface mannose
receptor levels, while dietary vitamin D deficiency in mice caused reduced F4/80 and
MAC-2 expression levels on primary cultured BMDM (192, 193). This suggests that
vitamin D signaling influences Mɸ maturation from bone marrow cells. Interestingly,
bone marrow cells from VDR KO mice developed similar amounts of Mɸ colonies
compared to those from mice with normal VDR, with or without M-CSF (191). This
implies that vitamin D is not necessary for BMDM development when M-CSF is
sufficient. Moreover, 1,25(OH)2D was proposed to induce monocytes differentiation into
Mɸs in vitro. 1,25(OH)2D alone significantly increased human PBMC MAX1 and MAX3
expression, induced cell adherence, and stimulated cell inflammatory response to LPS
(194, 195). Similarly, 1,25(OH)2D also induced CD14 and CD11b expression on THP-1
cells, suggesting induced Mɸ differentiation. (196-199). However, those cells derived
from THP-1 with increased Mɸ cell surface markers failed to become adherent, thus they
may not be matured Mɸs (196, 199). Collectively, the mechanism of vitamin D regulated
Mɸ differentiation requires further investigation to explain the discrepancy between
different experimental models. Due to practical reasons, whether vitamin D can induce
bone marrow myeloid precursors to develop into monocytes remains unclear. Monocytes
are differentiated from bone marrow hematopoietic stem cells, which is induced by MCSF and through PU.1 transcription factor (200). M-CSF can be produced by multiple
cell types including osteoblasts and human PBMCs, and the M-CSF expression can be
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elevated by 1,25(OH)2D treatment in culture (201, 202). Similar effects had been seen in
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induced THP-1 and HL-60
cell lines that 1,25(OH)2D induced the M-CSF production from cells (202). This suggests
that vitamin D signaling may regulate monocyte differentiation indirectly through
inducing M-CSF related signaling pathways. M-CSF binds to M-CSFR and activates
multiple connected signaling pathways. By activating Src kinase, both PI3K/Akt and
PLC-γ /PKC/ERK pathways can then be activated (200). These events will in turn
activate multiple transcriptional factors (e.g. C/EBPα, c-Jun, NF-κb etc.) and eventually
upregulate PU.1 expression and function (200). Among these pathway components,
1,25(OH)2D has been shown to increase PI3K activity in THP-1 cells, and VDR is
necessary to TCR induced PLC-γ1 expression in human T cells (198, 203). These results
indicate that vitamin D may be a potential monocyte lineage differentiation modifier by
regulating M-CSF initiated signaling pathways.
Vitamin D and monocyte/ Mɸ migration. Systemic inflammation induces bone
marrow monocyte production and emigration, thus increased circulating monocyte
numbers (204). Monocyte emigration from bone marrow is dependent on the MCP1/CCR2 pathway (204). Monocytes express high levels of CCR2 on the cell surface.
CCR2 deletion on monocytes caused monocyte accumulation in the bone marrow after
LPS injection in mice, and thus induced impaired systemic immune defense (204).
Vitamin D was proposed to have anti-migration effects partially through its suppression
of CCR2 expression on monocytes/ Mɸs (205, 206). MCP-1 is the chemokine ligand of
CCR2 which can be produced by multiple cell types. Among those, monocytes and Mɸs
are the major source of MCP-1 (207). Serum MCP-1 is mainly produced by circulating
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monocytes under steady state, which ensures newly differentiated monocytes emigrating
into the circulation and replenish blood monocyte population. Data showed that mouse
serum MCP-1 level was significantly elevated when fed a western diet containing low
vitamin D and calcium, and the chemokine level was reduced in mice with sufficient
vitamin D and calcium intake (208). Serum MCP-1 concentration is positively correlated
with circulating CD11b+ monocyte numbers in mice (209) and is upregulated in both
DSS and TNBS induced experimental colitis model in mice (210, 211). However,
whether low vitamin D signaling induces high serum MCP-1 levels or increased
monocyte numbers in blood circulation remains unknown. In vitro, LPS induced MCP-1
production by THP-1 cells and THP-1 induced Mɸs, and this pro-inflammatory effect
was significantly suppressed by 1,25(OH)2D pre-treatment in both groups of cells (212).
This suggests that 1,25(OH)2D may directly regulate blood monocyte MCP-1 expression
and thus induce bone marrow monocyte emigration.
Vitamin D signaling may also inhibit monocyte migration to local tissue mediated by
MCP-1. Colonic MCP-1 expression was increased in mice with DSS induced colitis, and
further elevated in mice with intestinal VDR deletion (206, 211). In Azoxymethane
(AOM)/DSS induced colon cancer mouse model, VDR deletion caused increased tumor
burden in colon with significantly increased MCP-1 expression level in colon tumor
(213). This suggests that vitamin D may also function on colon epithelial cells and reduce
their production of MCP-1, and therefore reduce monocyte migration into the colon.
Vitamin D and its immune suppressive function on monocyte/Mɸ. Monocytes
and Mɸs express VDR and the VDR activation can induce a significant
immunosuppressive effect on those cells (214). In human monocytes, 1,25 D treatment
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inhibited the expression of MHC class II antigens, including human leukocyte antigen
(HLA)-DR, HLA-DP, and HLA-DQ, all of which contribute to antigen presentation (215,
216). 1,25(OH)2D suppresses a variety of pro-inflammatory cytokines in human
monocyte/Mɸs cell lines mechanistically through suppressing AP-1 and NF-κB–mediated
pro-inflammatory pathways (217-219). The similar 1,25(OH)2D mediated immunesuppressive effect was also seen in mouse primary cell cultures. For example,
1,25(OH)2D treatment significantly suppressed LPS induced IL-1β and TNF-α expression
in mouse peripheral blood mononuclear cells (PBMC) and BMDM (220, 221), and IFN-γ
induced oxidative burst and host defense mediators, including CCL5, CXCL9, CXCL10,
FcγRI, and TLR2 in murine BMDMs (222). Since all of these immune-suppressive
effects were observed in activated monocytes/Mɸs, but not in resting cells, the
mechanism of 1,25(OH)2D induced anti-inflammatory response in monocyte/Mɸ is
proposed to be a feedback loop regulation (223).
Vitamin D and mature Mɸ polarization. Vitamin D modulates Mɸ activation and
polarization which then influences colitis related epithelial damage and healing. As has
been mentioned before, Mɸ polarization and activation are tightly related to colitis
development and recovery (73, 74, 224). NF-κB and STAT6 are two transcription factors
regulating M1 and M2 polarization respectively. LPS activated Mɸ NF-κB transcriptional
activity is inhibited by 1,25(OH)2D through increased IκB expression (225), while IL-4
activated STAT6 pathway might be induced by vitamin D (226-228). Evidence showed
that 1,25(OH)2D treatment increased STAT6 expression and enhanced Th2 polarization
in the multiple sclerosis (EAE) model (227), and THP-1 human monocyte cell line was
polarized to M2- like cells by 1,25(OH)2D (228). However, it is not clear whether STAT6
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is a 1,25(OH)2D direct target or whether the 1,25(OH)2D promotes M2 polarization
through this pathway. A recent study showed that 1,25(OH)2D can also induce M1 to M2
class switch. M1 Mɸs were polarized from RAW264.7 cell line by high glucose
treatment, characterized by high expression levels of TNF-α and IL-12(229). 1,25(OH)2D
treatment significantly reduced the M1 cytokine expression levels and increased M2
markers Arg1 and IL-10, potentially through upregulating PPARγ signaling pathway
(229).
Vitamin D and DC regulation. DCs are professional antigen presenting cells
(APCs) expressing both VDR and cyp27b1 (230). Even though DCs are developed from
the same hematopoietic lineage as monocytes/Mɸs, their response to vitamin D appears
to be maturation and antigen presentation regulation (230). While DCs are differentiating
into mature APCs, they express increased levels of cyp27b1, but reduced levels of VDR.
One explanation is that immature DCs with high VDR expression will respond to
1,25(OH)2D produced by mature DCs and undergo differentiation (231). This allows
some but not all DCs to become mature APC and therefore prevents an over-activated T
cell response that may cause further immune complications (231). VDR and cyp27b1 KO
mice developed abnormal lymphatic response presented by increased mature DC
numbers but reduced DCs trafficking (232) (233) (234). This emphasized the important
role of vitamin D in suppressing DC maturation and promoting DC migration. Similar to
Mɸ phenotypes mentioned above, DCs also have two different subtypes, myeloid DCs
(mDCs) and plasmacytoid DCs (pDCs). mDCs have higher efficiency to active naive T
cells while pDCs function as immune suppressive cells to attenuate T cell activation (80,
235). Even though mDCs and pDCs express similar levels of VDR, mDCs are
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1,25(OH)2D’s preferable regulating targets in vitro (236). This 1,25(OH)2D mediated
regulation on mDCs may further influence the downstream adaptive immune response.
1.5.2

Vitamin D and adaptive immune response

Adaptive immune cells, including T and B cells, also express VDR and are potential
vitamin D targets. T cells develop in the thymus and then leave after maturation. Premature T cells in the thymus express VDR, but the expression level will be dramatically
reduced once they emigrate into blood circulation. Activated T cells in secondary
lymphoid tissue will have their VDR expression recovered, suggesting that activated T
cells, not naïve T cells are vitamin D targets. Data showed that 1,25(OH)2D inhibits T
cell expansion induced by APCs in vitro, likely because 1,25(OH)2D inhibits T cell
proliferating cycle from early to late G1 phase.
Vitamin D also regulates T cell differentiation and activation. T cells are involved in
adaptive immune response as a diverse population, which can be further classified as
helper T cells, regulatory T cells and cytotoxic T cells. Among those, the effects of
vitamin D on helper T cells have been best characterized. Naïve T helper cells (Th0)
require APCs to be activated, and differentiated into Th1 (induced by IL-12, IFN-r), Th2
(induced by IL-4, 5, 10) or Th17 (induced by IL-23) based on cytokine profiles in the
microenvironment (237). In addition to suppressing effector T cell proliferation as
mentioned before, vitamin D can also regulates T cell activation and cytokine production.
Multiple studies showed that 1,25(OH)2D and its analogs reduced Th1 cytokine (e.g.
IFN-γ) production in vitro, (238-240), and a similar effect was also observed in disease
models in vivo. For example, vitamin D successfully prevented Th1 induced spontaneous
autoimmune disease development (e.g. SLE) in mice by inhibiting Th1 induced cytokine
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and IgG2a production (239). In addition, Boonstra et al. have demonstrated that vitamin
D also affects T cell differentiation by inhibiting Th1 and favoring Th2 (increased
production of IL-4, IL-5, IL-10) when the naïve T cells were co-cultured with either
splenic APC or the combination of anti-CD3 and anti-CD28 (241). Mechanistically,
vitamin D increased IL-4 induced Th2 transcriptional factors expression, including c-maf
and GATA-3 (241). 1,25(OH)2D can also suppress Th17 cytokine IL-17A expression in
both human and mouse T cells in culture (242). In the mouse EAE model (disease model
of human multiple sclerosis), 1,25(OH)2D injection attenuated disease severity by
suppressing IL-17A producing cell activity in the blood and central nervous system
(242).
In addition to regulating Th cell response, vitamin D also promotes CD4+CD25+Treg
induced anti-inflammatory and immune tolerogenic function (Barrat et al., 2002). The
mechanism of how vitamin D regulates Treg is still controversial. 1,25(OH)2D was first
demonstrated as an indirect regulator on Treg through suppressing DC maturation in vitro
(236). Subsequently, however, 1,25(OH)2D was described to directly influence CTLA-4
and Foxp3 positive Treg generation (243), and a functional VDR binding site VDRE was
found in the human Treg Foxp3 promoter region (244). Not only the active form
1,25(OH)2D but also the pro-hormone 25(OH)D were found to influence Treg
development. Jeffery et al. showed that 25(OH)D, especially non-DBP bound free
25(OH)D, has the ability to increase Treg generation through DCs (245). The importance
of vitamin D effect on Treg has also been illustrated in several in vivo studies. For
example, 1,25(OH)2D administration was used to treat chronic kidney disease by
increasing circulating Treg numbers in humans (246). In addition, the serum 25(OH)D
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concentration is significantly correlated with Treg activity in human MS (247, 248).
Similarly in mice, 1,25(OH)2D and its analog increased Treg cell numbers in the draining
lymph nodes (249, 250).
CD8+ cytotoxic T cell is another potential vitamin D regulating target due to the high
VDR and cyp27b1 expression levels (251, 252). CD8+ cytotoxic T cells are responsible
for defending against virus infection and cancer, and the effect of vitamin D on these
cells has recently been reviewed (253). A special group of CD8+ T cells, CD8αα+ T cells,
which do not have cytotoxic effects, may have an immune suppressive function in the GI
tract (254). Data showed that global VDR KO mice developed less CD8αα+ T cells in the
intestine which may associated with increased colitis severity (255). It may be caused by
reduced chemokine CCR9 expression and impaired T cell homing in VDR KO mice
(255).
Besides T cell response regulation, some early evidence showed that vitamin D can
also influence B cell proliferation and development (256, 257). The mechanism was
initially proposed as an indirect regulation through helper T cells. It was then
demonstrated that 1,25(OH)2D can directly inhibit plasma cell differentiation and
memory B cell class switch (238, 258). More recent reports showed that 1,25(OH)2D also
regulates B cell cytokine and chemokine production (e.g. IL-10 and CCR10), suggesting
additional roles besides regulating immunoglobulin secretion (259, 260).
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1.6

Vitamin D and epithelial barrier function

1.6.1

Vitamin D maintains gut permeability

The integrity of the gut barrier is the key to keep intestine homeostasis and prevent
chronic inflammatory diseases caused by “leaky gut”. Vitamin D has been proposed to
maintain gut permeability through regulating TJ, adherens junctions and epithelial cells
apoptosis.
1.6.1.1 Vitamin D and TJ in the gut
TJ is a special paracellular structure made of a complex of proteins. It seals the gaps
between epithelial cells and forms a barrier to prevent luminal molecules from invading
into deep tissue. The protein complex includes three parts: cytoskeletal proteins,
cytoplasmic proteins and membrane proteins. The major structural and functional
component of TJ proteins are Claundins, Occludins and “zonula occludens” (ZO) protein
family (261). In multiple experimental colitis studies, VDR deletion increased gut
permeability and 1,25(OH)2D treatment recovered the gut integrity. For example, Zhao et
al. observed that DSS-induced gut cellular permeability and bacteria translocation was
associated with impaired TJ, and 1,25(OH)2D intragastric administration significantly
recovered ZO-1, Occludin and Claudin-1 gene expression and protein levels in intestinal
mucosa (160). Vitamin D signaling also regulates the cellular location of TJ proteins
during infection. Assa et al. showed that E-coli infected Caco-2 cells had reduced TER
and paracellular permeability, potentially caused by internalization of TJ proteins.
1,25(OH)2D treatment prevented the pathogen induced redistribution of ZO-1 and
Claudin-1 thus rescued the single cell layer integrity in vitro (163). This effect was
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independently observed by Kong et al. that deleting VDR in Caco-2 cells resulted in the
internalization of TJ proteins (158). Christakos et al. also showed that 1,25(OH)2D
upregulated intestinal claudin-2 level (262), and the mechanism was later proved by
Zhang et al. that claudin-2 is a direct vitamin D regulating target (263). The Zhang group
found a VDRE site within the claudin-2 promoter region and proved that VDR directly
upregulated claudin-2 expression in both transcriptional and translational levels (263).
1.6.1.2 Vitamin D and adherens junctions
Adherens junction (AJ) proteins also form a complex to connect adjacent epithelial
cells in the intestine. Contrary to TJs, AJs are located at the basal part of epithelial cells.
AJ protein complex includes transmembrane proteins (e.g. E-cadherin) and intracellular
compartments (e.g. β-catenin). Cyp27b1 KO and VDR KO mice colon epithelial cells
expressed lower levels of E-cadherin after DSS treatment, indicating E-cadherin may be a
regulating target of vitamin D to protect against colitis (162). In vitro evidence
consistently showed that 1,25(OH)2D treatment increased E-cadherin expression in Caco2 cell culture and enhanced reconstitution after injury (158). Vitamin D regulated βcatenin activities have been mainly reported under colon cancer circumstances. Colon
cancer cells have β-catenin nuclear translocation, and 1,25(OH)2D treatment prevents βcatenin from entering the nucleus (264). This effect has only been seen in human SW480
cells with VDR expression but not those cell lines lacking VDR (e.g. SW620) (264). In
vivo, Apc min mice with VDR deletion resulted in increased β-catenin nuclear
translocation and colon tumor size (265). However, whether the regulating is applicable
to normal intestinal cells or relevant to IBD is still unclear.
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1.6.1.3 Vitamin D and intestinal epithelial apoptosis
Vitamin D induces colon cancer cell apoptosis, while inhibiting colon epithelial cell
death during mucosal healing. Previous studies on colon cancer cell lines showed that
vitamin D can directly upregulate bcl-2 and induce apoptosis (266). Indirectly, vitamin D
can inhibit Mɸ activation and IL-1β expression, therefore sensitizing colon cancer cell
response to TRAIL induced apoptosis (267). However, these mechanisms are restricted to
non-cancer colon epithelium. Under normal conditions, vitamin D protects colon
epithelial cell survival by reducing oxidative stress and DNA damage (268). Liu et al.
were later the first to report the anti-apoptosis role of vitamin D on colon epithelial cells
during experimental colitis (164). VDR KO mice were more susceptible to TNBSinduced colitis and their colon epithelial cells apoptosis rate (TUNEL staining) was
significantly higher than controls. They also showed that recovering intestinal VDR
reduced the apoptosis rate in intestine epithelial cells by suppressing the pro-apoptotic
molecule PUMA (164).
1.6.2

Vitamin D regulates Paneth cells function

About 3% of the mouse and human genomes are potentially regulated by vitamin D,
which indicates that vitamin D may be involved in the development of multiple diseases
(269). Specifically in IBD, two Paneth cell related anti-microbial genes, AMP and βdefensin, have been proved to be direct vitamin D regulating targets. In addition, IBD
risk is linked to dysregulated autophagy gene ATG16L1 which is also expressed in
Paneth cells and regulated by VDR target gene NOD2 (270). With this information, Wu
et al. conducted a study to investigate the direct effect of vitamin D signaling on Paneth
cell autophagy during experimental colitis (167). They found that intestine epithelial cell
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VDR KO increased colitis severity in mice with reduced ATG16L1 expression levels and
impaired autophagy function in Paneth cells. This regulation was independently
reproduced by knocking down VDR in culture. More importantly, they found a VDRE
site in the promoter region of mouse ATG16L1, and confirmed that it is a functional
VDR binding site using CHIP assay (167). This study filled the gap of vitamin D
regulation on Paneth cell autophagy function and its relationship with IBD development.

1.7

Research gaps

As has been discussed before, vitamin D mediated protection against IBD has been
seen in both human and animal models and the potential mechanisms are summarized in
figure 1.1. In mouse models, vitamin D signaling significantly reduced the severity of
experimental colitis at the acute stage. However, human IBD is often diagnosed at late
stage and the disease duration strongly affects IBD patients’ life quality and causes
further health issues. Therefore, the goal of human IBD management is to alleviate IBD
clinical symptoms with significant intestine mucosa healing. So far, the question of
whether or how vitamin D signaling influences mucosa healing is still to be answered.
More importantly, VDR is widely expressed in multiple cell types in the colon, and has
independent effects on colon epithelial cells and immune cells. Since they both contribute
to colitis development and recovery, it is important to know which type of cells plays a
more important role in vitamin D mediated protection against IBD. In the following
chapters, I will first introduce an animal model I developed, which was later used to
investigate colon epithelial cell VDR function in colitis induced mucosa healing (Chapter
2). I will then report the experiments I conducted to compare the impact of vitamin D
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between colon epithelial cells and immune cells during experimental colitis (Chapter 3).
Based on my own research data, I further investigated the regulatory effect of vitamin D
on one type of immune cells, Mɸs (Chapter 4). At the end of the thesis, I will discuss
future research directions (Chapter 5).
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Figure 1.1 Summary of the Potential Vitamin D Mediated Cellular Events
Relevant to IBD.
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2.1

Abstract

Background Animal models are an important tool to understand intestinal biology. Our
lab previously generated C57BL/6-Tg(Car1-cre)5Flt transgenic mice (CAC) with large
intestine specific Cre recombinase (Cre) expression as a model to study colon health.
Aims To expand the utility of the CAC mouse model by determining the impact of
chemically induced colitis on CAC transgene expression.
Methods CAC mice were crossed to Rosa reporter mice (Rosa26Rflox/flox) with a loxSTOP-lox signal controlling -galactosidase (gal) expression and then further crossed with
ApcCKO/CKO mice in some experiments to delete Apc alleles (ApcΔ580) Initially, 8-wk-old
CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice were treated with dextran sulfate sodium (DSS) in
drinking water (5 d, 0, 0.65%, 1.35%, or 2.0%). Colon tissue damage and gal labelling were
analyzed 10-d after stopping DSS. Next, 8-wk-old CACTg/WT;Rosa26Rflox/flox mice were treated
with 0 or 1.35% DSS, and colonic β-gal labeling was assessed at 30-d post DSS treatment.
Finally, 10-wk-old CACTg/WT;ApcΔ580/WT mice were treated with DSS (0 or 2%) for 5 d and
colonic tumors were analyzed at 20-wk.
Results CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice had a DSS dose-dependent increase in
colon epithelial damage that correlated with increased epithelial β-gal labeling at 10-d (r2 =
0.9,  = 0.75). The β-gal labeling in CACTg/WT;Rosa26Rflox/flox mice colon remained high at 30-
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d, especially in the crypts of the healed ulcer. DSS also increased colon tumor incidence and
multiplicity in CACTg/WT;ApcΔ580/WT mice.

2.2

Introduction

Colorectal cancer is a multi-factorial disease and its development can be influenced by
genetics, diet, inflammation, environment and other factors (1-6). Unfortunately, the etiology
of colorectal cancer remains unclear, thus barriers exist to develop approaches to prevent and
treat the disease (7-9). Controlled animal studies are an important approach to understand
colorectal cancer biology and to test promising strategies for disease prevention and treatment.
As such, an optimal animal model of colorectal cancer should capture the pathological changes,
molecular mechanisms, and clinical symptoms presented in the human disease. In addition, the
cancer effect should be limited to colon to avoid the confounding effect of cancer in other
tissues.
Many animal models have been developed for colorectal cancer research, and they have
been reviewed in several recent comprehensive reviews (10-12). Our lab previously generated
a transgenic mouse model for colorectal cancer research with large intestine-specific Cre
recombinase (Cre) transgene expression, i.e. the C57BL/6-Tg(Car1-cre)5Flt or CAC mouse
(13). In colon epithelial cells of CAC mice, Cre is expressed in approximately 10% of the
epithelium. Here we report that Cre expression in colon epithelial cells of CAC mice can be
increased during dextran sulfate sodium (DSS) induced colitis. In addition, our data suggest
that these recombination events induce a persistent effect that can be used to study genes
involved in the epithelial response to colitis or in colitis-associated colon cancer.
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2.3

Materials and Methods
2.3.1

Animals

C57BL/6-Tg(Car1-cre)5Flt mice were created by our group (13) and maintained as
heterozygotes (CACTg/WT). The Rosa26R strain, B6.129S4-Gt(ROSA)26Sortm1Sor/J, was
obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained as homozygotes
(ROSAflox/flox). Rosa26R mice contain a STOP sequence that is flanked by LoxP sites upstream
from the E. coli β-galactosidase (βgal) gene within a gene trap of the Rosa26 allele (14). The
ApcCKO mouse carrying a floxed exon 14 of the Apc gene (ApcCKO/CKO) was obtained from the
Mouse Models of Human Cancer Consortium (National Cancer Institute, Frederick, MD). In
cells expressing Cre, exon 14 is removed resulting in a truncated 580 amino acid long protein
produced from one (ApcΔ580/WT) or both (ApcΔ580/Δ580) Apc alleles. Genotypes were determined
by standard PCR methods as previously described for the CAC (13), Rosa26R (14), and floxed
Apc alleles (13). Each strain of mouse was maintained on a C57BL/6J background. Mice were
bred to create experimental animals with specific combinations of genotypes. All mouse
breeding colonies were housed individually, given a standard chow diet and water ad libitum,
and exposed to a 12 hours light/12 hours dark cycle. The experiments were conducted with
approval from the Purdue University Animal Care and Use Committee.
2.3.2

Experimental Design

Experiment 1: CACTg/WT;Rosa26Rflox/flox mice were crossed to ApcCKO/CKO mice to
generate CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice. Experimental mice were weaned at 3
weeks of age and fed the AIN93G diet (15). Mice were randomly assigned into one of four
dextran sulfate sodium (DSS) treatment groups (0%, 0.65%, 1.35% and 2%, n=16 per group,
8 male and 8 female). DSS (MW = 36,000-50,000 Da, MP Biomedicals, LLC, Solon, OH) was
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diluted in deionized water (w/v) to the appropriate concentrations. At 8 weeks of age, mice
received the DSS solution in place of water ad libitum for 5 consecutive days. Afterwards,
DSS was replaced with deionized water and this was provided until the day of sacrifice. Half
of the mice in each group were sacrificed 2 days after ending the DSS treatment and half were
sacrificed 10 days after ending DSS treatment. All mice were fasted overnight before harvest.
At necropsy, the proximal and distal colon were prepared as Swiss rolls and examined for βgalactosidase levels by immunohistochemistry.
Experiment 2: 24 CACTg/ WT;Rosa26Rflox/flox mice (12 female and 12 male) were weaned
at 3 weeks of age and fed AIN93G diet. At 8 weeks of age, 16 mice (8 male and 8 female)
were treated with 1.35% DSS for 5 days and the other 8 mice (4 male and 4 female) were used
as vehicle controls (0% DSS). Half of the DSS treated mice and all the vehicle control mice
were sacrificed 10 days after completing the DSS treatment. The other mice in the DSS
treatment group were sacrificed 30 days after completing the DSS treatment. All mice were
fasted overnight before harvest. At necropsy, the proximal and distal colon were prepared as
Swiss rolls and examined for β-galactosidase levels by immunohistochemistry. Small intestine,
kidney, spleen, liver and lung were also collected for detection of β-galactosidase enzymatic
activity.
Experiment 3: 13 CACTg/WT;Rosa26Rflox/WT;ApcΔ580/Δ580 mice with two recombined Apc
alleles were generated by crossing CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice with ApcCKO/CKO
mice. Mice were sacrificed at 4 weeks of age after an overnight fast. At necropsy, the proximal
and distal colon were prepared as Swiss rolls and examined for β-galactosidase levels by
immunohistochemistry.
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Experiment 4: 81 CACTg/WT;ApcΔ580/WT mice were generated by crossing CACTg/WT mice
with ApcCKO/CKO mice. CACTg/WT;ApcΔ580/WT pups were weaned at 3 weeks of age and fed an
AIN93G diet. CACTg/WT;ApcΔ580/WT mice were treated with either 2% DSS (n=38) or deionized
water (n=43) at 10 weeks of age for 5 days, then the DSS was replaced with water. Mice were
sacrificed at 20 weeks of age after an overnight fast. The colon was removed, opened
longitudinally, and cleaned with PBS. Digital images were collected and analyzed to determine
the number, location, and size of each tumor.
2.3.3

Detection of β-galactosidase Activity in Organs

Tissues were dissected from the mice, rinsed briefly in cold PBS, and fixed for 1-2 hours
in ice cold 4% paraformaldehyde. After rinsing the tissue for 15 minutes in PBS, tissues were
incubated for 4 hours in 1 mg/mL 5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside (X-gal;
Invitrogen; B-1690) solution (pH 7.6) at 37°C as previously described (13). In tissues
expressing βgal (indicative of Cre-mediated recombination of the Rosa26R locus), the enzyme
converted the X-gal substrate into a dark blue crystalline precipitate that is visible upon gross
examination.
2.3.4

Tissue Preparation and Immunohistochemical Detection of β-galactosidase

The colon was opened longitudinally, rinsed with cold PBS, and transected at its midpoint
to separate the proximal and distal colon. Each section was split longitudinally and Swissrolled (16), resulting in 2 rolls of proximal colon and 2 rolls of distal colon per mouse. Tissues
were immersion fixed for 48-72 hours in 10% neutral buffered formalin at 4°C before being
transferred to 70% ethanol. Tissues were processed and embedded in paraffin within 7 days of
collection at the Purdue Histology and Phenotyping Laboratory.
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Four micron tissue sections were cut, de-paraffinized, and rehydrated through xylene,
ethanol, and water by standard methods. For antigen retrieval, slides were submerged in 0.01
mol/L sodium citrate (pH 6.0) and heated to 96°C for 20 minutes in a laboratory microwave
(PELCO, Edmond, OK). Immunohistochemistry was performed on a Dako Autostainer (Dako,
Denmark). Slides were incubated with 0.03% hydrogen peroxide (5 minutes) and serum-free
protein block (30 minutes; Dako; Denmark), followed by a 120 minute incubation with rabbit
polyclonal anti–β-galactosidase (β gal) antibody (1:400 dilution; Novus; NB100-65209).
Antigen binding was detected with a horseradish peroxidase–labeled anti-rabbit IgG polymer
(Vector laboratories; MP-7410) and 3, 3’-diaminobenzidine (DAB; Vector laboratories; SK4100) as the chromogen. Slides were counterstained with Harris hematoxylin (EK Industries,
Juliet, IL). The digital images were collected with an Aperio ScanScope slide scanner (Leica
Technologies, Buffalo Grove, IL) at 20X magnification.
2.3.5

Image Analysis

Mucosal transgene expression was determined by quantifying the percent βgal positive
pixels after immunohistochemistry. The colonic mucosa was differentiated from the tunica
muscularis using the Genie histology pattern recognition software (Aperio, Leica Biosystem)
trained at 5X magnification and 1000 iterations to a mean training accuracy of 96%. A positive
pixel count algorithm was then used to analyze DAB labeling within the mucosa. This analysis
was done by a board certified veterinary pathologist (RLJ) and confirmed independently (by
FW).
The area of βgal positive crypts was determined by manually measuring the length of the
mucosal surface containing βgal labeled crypts. βgal positive crypts were included only if the
entire crypt axis, from base to lumen, was within the plane of section or if the crypt base could
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be seen immediately adjacent to the muscularis mucosa. The percentage of area represented by
βgal positive crypts was calculated by dividing the length of the βgal positive area by the total
length of the mucosa surface.
The damaged tissue surface area included the areas of ulceration and areas undergoing
active healing. Ulceration was defined as sections of the colon mucosa devoid of crypts. This
phenotype is obvious at day 2 after DSS termination and increased with DSS dose. Tissue
healing included restitution (a single layer of epithelial cells covering an ulcer bed), crypt
fission, and crypt regeneration - two events that repopulate the organized crypt structure within
an ulcer. These phenotypes were observed at day 10 after DSS termination and continued
through day 30 after DSS termination. The percentage of damaged surface was defined as the
length of damaged mucosa divided by the total length of the mucosal surface.
2.3.6

Statistical Analysis

Statistical analysis was performed with SAS Enterprise 5.1 software (SAS Institute, Cary,
NC). All data were reported as the mean ± standard error of the mean (SEM). Normality of the
data was determined by evaluation of its histogram and a Shapiro-Wilk normality test (p>0.05).
All of the data were normally distributed. Statistical comparisons were made by two-tailed
student’s t-tests, one-way ANOVA or Chi-square test as appropriate. Following one-way
ANOVA, the Bonferroni multiple comparison test or planned orthogonal contrasts were used
to compare groups. Differences were considered significant at p ≤ 0.05 for all the statistical
comparisons.
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2.4
2.4.1

Results

Cre-mediated recombination is increased by DSS treatment in
CACTg/WT;Rosa26Rflox/WT; ApcΔ580/WT mice.

Our group has previously reported that CAC mice have recombination of the Rosa allele
that is restricted to the large intestine epithelial cells (13). In our experiments, β-gal labeling is
used as an indicator of Cre-mediated transgene recombination. In experiment 1, we examined
the proximal and distal colon of CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice without DSS
treatment (Fig 2.1A-D). The proximal colon under the basal, non-DSS condition had
significantly more β-gal positive cells than the distal colon (Fig. 2.1E, p=0.0023). However, βgal labeling in proximal colon was mostly superficial, while entire crypts were labeled in distal
colon (Fig. 2.1B, D). As a result, 5-fold more β-gal positive crypts were observed in the distal
colon than the proximal colon, (Fig. 2.1F, p=0.0011).
Ten days after DSS treatment β-gal labeling was significantly increased at all three DSS
doses (Fig. 2.2A, vehicle vs DSS, Proximal colon: p<0.0001; Distal colon: p=0.0007). In both
the proximal and distal colon, a significant increase in β-gal labeling was observed as more
DSS was used, although the labeling plateaued in the 2% DSS treatment group (Fig. 2.2A). In
addition, the increased β-gal labeling was present from the surface to the crypt base in both
colonic segments (Fig. 2.3). The impact of DSS treatment on β-gal activity was also examined
in the small intestine, liver, spleen, lung and kidney. As reported previously (13), β-gal activity
was not observed in the small intestine, even after DSS induction (data not shown). Both liver
and lung had low level baseline transgene recombination but this was not increased by DSS
treatment. Kidney had non-specific β-gal activity in non-transgenic mice but this did not
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increase in either the CAC mouse or the CAC mouse treated with DSS. In the spleen there was
no transgene expression either at baseline or after DSS treatment (Fig. 2.4).
As expected, the percentage of damaged epithelial surface was higher with increasing DSS
dose in both proximal and distal colon (Fig. 2.2B). In addition, there was a direct, positive
correlation between epithelial damage and β-gal expression in both colonic segments (r2 >0.9,
slope = 0.75, Fig. 2.2C). Also, regardless of the DSS dose, approximately 60% of the abnormal
crypts in the areas of epithelial damage were β-gal positive (data not shown). This indicates
that Cre-mediated recombination of the LacZ locus has occurred in the epithelium that
expanded to heal the DSS induced ulcers.

2.4.2 Increased β-gal expression resulting from DSS induced colon damage is sustained
after tissue recovery.
In normal colon mucosa, the crypts are well organized and separated by very little lamina
propria (Fig 2.5A, B). 10 days after DSS treatment, the ulcerated mucosa was undergoing
active healing, characterized by epithelial restitution, crypt fission, and crypt regeneration (Fig
2.5C, D). By 30 days after DSS treatment, the ulcerated mucosa was filled with normalappearing crypts that were separated by slightly increased amounts of lamina propria (Fig 2.5E,
F). As we observed in the first study, the total percentage of β-gal positive crypts was
significantly higher in the DSS treatment groups than the vehicle controls at 10-day post DSS
(proximal colon in Fig. 2.6A, p<0.0001, distal colon in Fig. 2.6D, p=0.0024) and greater than
60% of the crypts in the healing ulcer were β-gal positive (Fig. 2.6B, E). This increased β-gal
staining remained 30 days after termination of DSS treatment (Fig. 2.5, Fig. 2.6, and Fig. 2.7).
In fact, the percentage of β-gal positive crypts in the healing/healed ulcer was higher at 30-day
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post DSS than 10-day post DSS (e.g. 75.2±4.4 % vs 57.9±6.3 % in proximal colon). The DSS
treatment group also had significantly more β-gal positive crypts in areas of normal-appearing
crypts that were adjacent to healing mucosa (Fig. 2.6C, F, Proximal colon: p<0.0001; Distal
colon: p=0.0001). This indicated that the transgene expression induced by DSS was sustained
in the tissue after recovery of the damaged epithelium.

2.4.3

DSS induced transgene recombination increases tumor formation.

We first examined whether β-gal staining occurs coincident with adenomatous phenotypes
that result from deletion of two floxed Apc alleles. In CACTg/WT;Rosa26Rflox/WT;ApcΔ580/Δ580
mice, 30% of the distal colon exhibited an adenomatous phenotype consistent with
recombination of both Apc alleles (i.e. increased cytoplasmic basophilia, increased nuclear to
cytoplasmic ratio, loss of nuclear basal polarity, disruption of crypt architecture). While only
2.4% of crypts in normal mucosa were β-gal positive (Fig. 2.8A), within the adenomatous
regions 88.8±1.5% of the epithelial cells were positive for β-gal (Fig. 2.8B). The co-occurrence
of β-gal labeling (indicative of recombination at the ROSA26R locus) and the adenomatous
phenotype (indicative of recombination of both floxed Apc alleles) suggests that Cre mediated
recombination of floxed alleles is very efficient.
Since DSS treatment induces Cre-mediated recombination in crypts, we hypothesized that
DSS would increase tumor incidence in CACTg/WT;ApcΔ580/WT mice by expanding the colonspecific inactivation of a single Apc allele, coupled with the well-established tumor-promoting
effects of inflammation (17). In the vehicle treated group, 18.6% of the mice had a colonic
tumor and the tumors were all in the distal colon (Table 2.1, 1.25 per mouse). In contrast, DSS
treatment significantly increased the percentage of mice with colonic tumors to 78.9% (DSS
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vs Vehicle, p<0.0001) and this included the appearance of tumors in the proximal colon in 34%
of mice. The number of colonic tumors developed per mouse was also significantly higher in
the DSS treated mice compared to the vehicle controls (4.20 vs 1.25 per mouse, p<0.0001).
The DSS treatment resulted in twice as many mice with tumors in the distal colon compared
to the proximal colon (Table 2.1, 74% vs 34%, respectively) and twice as many tumors in the
distal versus the proximal colon (Table 2.1, 3.71 vs 1.47 per mouse, respectively). Thus the
CAC mediated recombination of Apc alleles induced by DSS along with the pro-inflammatory
environment within DSS-induced ulcers was a potent promoter of colon cancer.

2.5

Discussion

Our results expand the utility of the CAC mouse model by demonstrating that
recombination of floxed alleles driven by the Cre recombinase transgene is increased during
DSS-colitis. This effect was restricted to large intestinal epithelial cells, was tightly correlated
with DSS-induced epithelial damage, was visible during the healing of ulcers, and persisted in
crypts within the healed epithelium. However, since DSS causes colon epithelial damage that
is accompanied by local inflammation, it is not clear whether induction of transgene activity is
a result of the epithelial damage, healing, inflammation, or the factors combined.
While the mechanism for this effect is not known, two lines of evidence suggest that the
colonic stem cell has been affected. First, recombination is evident in epithelial cells from the
luminal surface to the crypt base where colon stem cells reside, and second, the effect is
persistent in crypts and lasts after the damaged epithelium has healed. Lgr5+ cells have been
identified as rapid turnover intestinal stem cells (18) that maintain the intestinal epithelium
(19). However, Lgr5+ stem cells are absent from the DSS damaged areas of the distal colon
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(20). Other putative intestinal stem cells with moderate proliferative capacity have been
identified including cells marked by Tert, Bmi1, Hopx, and Lrig1+ cells. These stem cells may
interconvert to maintain the intestinal epithelium, especially under stress, e.g. as seen when
Bmi1+ cells serve as the stem cell reservoir in the small intestine when Lgr5+ cells are deleted
(21, 22). Although Bmi1+ cells are not present in the colon (21), Lrig1+ cells are found in there
(23). We hypothesize that CAC transgene expression may be activated in Lrig1+ cells during
healing and that recombined floxed alleles are retained in Lrig1+ cells which then pass them
to new Lgr5+ cells that repopulate the epithelium after ulcer healing. Further experiments
examining transgene expression in Lrig1+ and Lgr5+ cells before, during, and after DSS
induced colitis need to be done to test the hypothesis.
In addition to the CAC mouse we developed and used in these experiments (13), several
other mouse models exist for colon research and each have advantages and disadvantages (11).
A 12.4 kb region of the mouse villin promoter drives Cre recombinase expression uniformly
throughout the epithelial cells of the intestine (24). However, villin-Cre transgene expression
extends into the small intestine (24) and this can confound interpretation of events occurring
in the colon. An improvement on the villin-Cre mouse was accomplished by using a 9 kb villin
promoter to drive a CreERT2 transgene that is tamoxifen inducible and which can cause gene
deletions that are spatially and temporally controlled. However, 60 days after treating villinCreERT2 mice with tamoxifen, the persistence of recombination in small intestine was seen in
80% of the epithelium while in the colon it was just 40% (25). Moreover, villin promoter driven
Cre or Cre-ERT2 transgene expression level is lower in the crypt base where stem cells are
found (24, 25) and this suggests that Cre activity in the colon stem cell compartment may not
be sufficient for optimal recombination.
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Deletion of floxed alleles directly in intestinal stem cells can be accomplished using the
Lgr5 promoter-CreERT2 mouse (26) and the Lrig1 promoter-CreERT2 mouse (23).
Unfortunately, inducible Cre-ERT2 transgene activity is very low in the large intestine of Lgr5
promoter-CreERT2 mice (27) and so, like the villin promoter models, the Lgr5 promoterCreERT2 mouse is best for inducing small intestinal cancer. The Lrig1 promoter-CreERT2
mouse forms multiple adenomas in the distal colon when it is used to delete an Apc allele;
however, many tumors are also seen in the small intestine (23).
An improvement on these models is the CDX2 promoter-Cre mouse whose transgene
expression is seen only in cecum, colon and distal ileum of adult mice. When it is used to delete
a floxed Apc allele, tumors form in the ileum and distal colon (28). Unfortunately, transient
expression of the CDX2-Cre transgene during embryonic development causes recombination
of floxed alleles throughout the distal half of the body. This could reduce the utility of the
CDX2-Cre model for many genes whose functions are present outside the colon. A tamoxifeninducible version of this model, CDX2-CreERT2, avoids the problem of embryonic transgene
recombination (27). However, the induced transgene activity is much higher in proximal colon
than the distal colon so its utility may be limited.
Our original CAC model (13) has a major advantage over the other models just described
-intestinal transgene expression is specific to the large intestine. This makes the model useful
to study the role of specific genes in basic colonic biology and in cancer. A weakness of the
CAC model is that CAC transgene expression affects just a small portion of the colonic
epithelium and extends to the crypt base mostly in the distal colon. Here we report a major
advance for the CAC mouse – that Cre-mediated recombination is induced during DSSmediated epithelial damage in the colon. The effect of DSS-induced colitis on CAC transgene
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activity occurs to a comparable degree in both the proximal and distal colon. The DSS/CAC
model also has the advantage that the increase in transgene activation is directly related to the
dose of DSS used but that increase does not involve the entire mucosa. For example, we found
that only 40-50% of the epithelial surface in the distal colon became transgene positive after
treating mice with 2% DSS for 5 days. Thus, in this model both normal tissue (without
transgene expression) and tissue with recombined alleles will be adjacent to one another. This
will reduce the biological variation caused by intra-animal differences by providing an internal
control for paired analysis of treatment effects.
An obvious use of the DSS/CAC model is to delete cancer-relevant genes and assess their
impact on inflammation-induced colon cancer. As a preliminary test of this application, the
DSS/CAC model was used to delete Apc gene alleles in the context of DSS-induced colitis.
We found that in CAC mice with one inactivated Apc allele, DSS increased colonic tumor
incidence 4-fold (to 78.9%) and tumor number per mouse 3-fold (to 4.5 colonic tumors per
mouse). While this revealed the utility of our model, it also revealed a segment-specific risk
for colon cancer. Despite the fact that DSS-induces recombination of floxed alleles equally in
both proximal and distal colon, tumors formed predominantly in the distal colon. This suggests
that the different environmental influences interact with inflammation and Apc allele loss to
affect cellular transformation and tumor development in the proximal and distal colon.
Several other applications for the new DSS/CAC model could also benefit the colon
cancer or IBD research community. First, since the CAC transgene is activated in epithelial
cells during active colitis, our model could provide insight into the epithelial role of specific
genes during active inflammatory bowel disease and during the epithelial healing response.
For example, several novel genes have been proposed to influence colitis and colitis-induced
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colon cancer through their impact on mucosal healing (e.g. NLRP6, TLR9, JAK3, FAK) (2932). However, most of those genes are expressed in multiple cell types within the colon
inflammatory microenvironment (e.g. NLRP6 is expressed in epithelial cells as well as
macrophages, T cells, and B cells (33)). Because of this, the results from studies with global
gene deletion models are confounded but the DSS/CAC model will allow one to overcome this
problem and target the gene disruption directly to the site of ulceration and epithelial healing.
Second, our model may allow researchers to examine the importance of specific genes in
field cancerization (34-36). This concept suggests that the cancer development starts in
relatively large areas of tissue due to early pro-tumorigenic alternations. These mutations may
not be sufficient to cause cancer but they predispose the tissue to further cancer-causing
mutations. The molecular alterations that create a field or push a field towards cancer can be
induced by micro-environmental triggers like colonic inflammation. For example, multiple
bouts of tissue damage and repair in IBD patients increases colon cancer risk (37). In patients
with Ulcerative Colitis who have developed neoplasia, TP53 or KRAS mutations can be
detected in both the neoplastic area and non-dysplastic crypts (38). This suggests that the
mutated cells had populated a large field of mucosa prior tumor formation. Our DSS/CAC
model can be used to generate a wide spread field cells with specific gene mutations in the
colon.
In summary, we observed a novel phenotype for the CAC model - that the Cre transgene
mediated recombination is induced following DSS treatment. This opens the opportunity to
study gene function at the time of colitis development as well as after the recovery of colitis.
We believe the DSS/CAC model is an efficient, reliable model for research on the epithelial
cell biology of colitis and inflammation-induced colon cancer. This will make the CAC/DSS
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model a powerful tool to study the mechanisms by which inflammation alters the colonic
epithelium (including cellular transformation) as well as to assess interventions to minimize
the impact of inflammation on colonic diseases.
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Table 2.1 DSS Increases Tumor Incidence in CACTg/WT;ApcΔ580/ WT Mice
Vehicle
#

Incidence

DSS
# per

n

#

Incidence

# per

Tumors

(%)

mousea

n
Tumors

(%)

mousea

Any Tumor

9

12

20.9

1.33±0.24

37

186

97.4*

5.03±0.56#

Cecum

2

2

4.7

1.00±0.00

30

60

81.6*

2.00±0.32#

Proximal colon

0

0

0.0

0.00

15

22

34.2*

1.47±0.29#

Distal colon

8

10

18.6

1.25±0.25

28

104

73.7*

3.71±0.35#

Proximal + Distal

8

10

18.6

1.25±0.25

30

126

78.9*

4.20±0.40#

No Tumor

34

0

79.1

1

0

2.6

Total Mice

43

38

Notes: Significantly different from the vehicle group (* Chi-square test, p<0.05; # Student’s
T-tests, p<0.05).
a
Average number of tumors per tumor-bearing mouse
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Figure 2.1 Baseline βgal expression patterns are different between proximal and distal colon
in CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice.Colons from 10 weeks old mice were prepared
as Swiss rolls, processed, and stained for β-gal expression by immunohistochemistry.
Representative images were generated using an Aperio ScanScope digital slide scanner and
are presented for proximal colon (A, B) and distal colon (C, D), The top pictures are at 2X
magnification and the bottom pictures are at 20X magnification. (B) β-gal labeling in
proximal colon Swiss rolls was predominantly superficial (arrow head) with occasional
labeling to the crypt base (arrow). (D) β-gal labeling in distal colon Swiss rolls was seen
from the crypt base to the luminal surface (arrow). (E) Total mucosal β-gal positive pixels
and (F) β-gal positive crypts were quantified. The bars represent the means ± SEM of 8
animals for data from the proximal colon and distal colon. * p< 0.05 vs CoP.
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Figure 2.2 Colon β-gal expression is positively correlated with epithelial damage in
CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice following DSS treatment. Mice were given
increasing amounts of DSS for 5 days then examined histologically 10 days later. (A) The
percentage of β-gal positive crypts in the proximal or distal colon. (B) The percentage of
damaged epithelium (includes colon epithelial ulceration, restitution, crypt fission and other
abnormal crypt structures observed during the healing process). Bars represent the mean ±
SEM of 8 animals per group. Planned orthogonal comparisons were performed between no
DSS vs the DSS treatment groups (# p<0.05), the low DSS vs high DSS groups (* p<0.05),
and the two high DSS groups (not significant). (C) The relationship between the percentage
epithelial damage and β-gal positive area in colon. The regression line for the proximal colon
is shown as a dashed line. The regression line for the distal colon is shown as a solid line.
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Figure 2.3 Immunohistochemical labeling for βgal in proximal and distal colon of DSStreated CACTg/WT;Rosa26Rflox/WT;ApcΔ580/WT mice. Animals were treated with 2% DSS for 5
days, and the tissues were collected at 10 days after stopping DSS treatment. Representative
images were generated using an Aperio ScanScope digital slide scanner and are presented for
proximal colon (A, B) and distal colon (C, D). The top pictures are at 2X magnification and
the bottom pictures are at 20X magnification. Arrow head = normal crypt structure adjacent
to a healing area. Arrow = crypt fission phenotype within a healing area.
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Figure 2.4 βgal expression in extra colonic tissues (spleen, lung, liver and kidney) was not
induced by DSS treatment. Tissues were harvested, prepared, and βgal activity was detected
as described for the colon. Blue staining represents βgal enzymatic activity. (A) Negative
control: mice lacking the Cre-recombinase transgene. (B) βgal activity in
CACTg/WT;Rosa26R flox/flox transgenic mice without DSS treatment. (C) βgal activity in
CACTg/WT; Rosa26R flox/flox mice 10 days after completing a 5 day course of 1.35 % DSS.
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Figure 2.5 After DSS treatment transgene expression is increased in regenerating crypts and
is sustained after healing of ulcers in distal colon. (A, B) Representative images of βgal
expression level in the distal colon of a CACTg/WT;Rosa26Rflox/flox mouse treated with vehicle
under 2X (A) and 20X (B) magnification. Crypt base labeling is highlighted with arrow head.
(C, D) Images of βgal labeling in a CACTg/WT;Rosa26Rflox/flox mouse 10 days after the end of
treatment with 1.35% DSS under 2X (C) and 20X (D) magnification. (E, F) Images of βgal
labeling in a CACTg/WT;Rosa26Rflox/flox mouse 30 days after the end of treatment with 1.35%
DSS under 2X (E) and 20X (F) magnification. In (C, D, E, F), Arrow = βgal positive crypts
undergoing regeneration. Arrow head = β-gal positive crypts with normal phenotype adjacent
to a healing area. All the images were generated using an Aperio ScanScope digital slide
scanner.
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Figure 2.6 The percentage of β-gal positive crypts increases after DSS treatment and is
sustained after regeneration in the colon of CACTg/WT;Rosa26Rflox/flox mice. (A, D) The
percentage of β-gal positive crypts was measured in proximal (A) and distal (D) colon at 10
or 30 days after ending DSS treatment. Means with different letters are significantly different
(Bonferroni, p< 0.05). (B, E) The percentage of β-gal positive crypts in mucosa that exhibits
a healing phenotype in the proximal (B) and distal (E) colon. Student t-tests were used to
compare values between day 30 and day 10 (* p<0.05). (C, F) The percentage of βgal
positive crypts in normal mucosa was measured in proximal (C) and distal (F) colon. Planned
orthogonal comparisons were performed (* p<0.05, day 0 vs post-treatment values; $ p<0.05,
day 10 vs day 30; # p<0.10, day 10 vs day 30). Bars represent the mean ± SEM of 8 animals
per group.
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Figure 2.7 Transgene expression is increased in regenerating crypts and is sustained after
healing in proximal colon. (A, B) Representative images of βgal expression level in the
proximal colon of a CACTg/WT;Rosa26Rflox/flox mouse treated with vehicle under 2X (A) and
20X (B) magnification. Crypt base labeling is highlighted with arrow head. (C, D) Images of
βgal labeling in a CACTg/WT;Rosa26Rflox/flox mouse 10 days after the end of treatment with
1.35% DSS under 2X (C) and 20X (D) magnification. (E, F) Images of βgal labeling in a
CACTg/WT;Rosa26Rflox/flox mouse 30 days after the end of treatment with 1.35% DSS under
2X (E) and 20X (F) magnification. In (C, D, E, F), Arrow = βgal positive crypts undergoing
regeneration. Arrow head = β-gal positive crypts with normal phenotype adjacent to a
healing area. All the images were generated using an Aperio ScanScope digital slide scanner.
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Figure 2.8 Colon tissue with an adenomatous phenotype show high βgal expression level in
4-week-old CACTg/WT; Rosa26Rflox/WT; ApcΔ580/Δ580 mice. (A) βgal expression in a normal
area of the distal colon. Arrow = βgal labeling in a normal crypt. (B) βgal expression in distal
colon adenomatous phenotype. Arrow = adenomatous phenotype with βgal positive labeling.
Arrow head = adenomatous phenotype with βgal negative labeling. Images were generated
using an Aperio ScanScope digital slide scanner. Magnification: 20X.

85

CHAPTER 3.
VITAMIN D RECEPTOR-DEPENDENT SIGNALING IN BOTH
COLONIC EPITHELIAL AND NON-EPITHELIAL CELLS PROTECTS MICE FROM
DEXTRAN SULPHATE SODIUM-INDUCED COLITIS

Fa Wang1, Robert L. Johnson2, Marsha DeSmet3, Paul W. Snyder2,4, and James C. Fleet1,4
1. Department of Nutrition Science, 2. Department of Comparative Pathobiology, 3. Purdue
University Interdisciplinary Life Sciences Ph.D. Training Program, Purdue University, and 4.
Center for Cancer Research, West Lafayette, IN 47907
Corresponding Author:
James C. Fleet, PhD
Department of Nutrition Science
Purdue University
700 West State St.
West Lafayette, IN 47907-2059
fleet@purdue.edu
Phone: (765) 494-0302
Fax: (765) 494-0906

Keywords: Vitamin D, Vitamin D Receptor, Transgenic mice, Dextran Sulphate Sodium,
Colitis, Colon Epithelial Cell, Immune Cell, Mɸ

86
3.1

Abstract

Low vitamin D status is associated with an increased risk of inflammatory bowel
disease in humans while low dietary vitamin D intake increases the severity of dextran
sulphate sodium (DSS)-induced colitis in mice (Pilot study). However, it is not clear
which cells in the inflamed colon are vitamin D targets and contribute to the enhanced
colitis seen in vitamin D deficiency. We tested the hypothesis that the vitamin D receptor
(VDR) has independent roles in colonic epithelial cells and in non-epithelial cells
(primarily infiltrating immune cells) during experimental colitis. We further conducted
two studies where VDR was deleted from either colon epithelial cells (study 1) or nonepithelial cells (Study 2) in mice with experimental colitis. 8-wk-old mice were treated
with 1.35% DSS for 5 days then killed 10 day after completing the DSS treatment. Body
weight (BW) loss, disease activity index (DAI) and spleen weight were assessed as
systemic measures of colitis severity. Colitis was measured histologically in colon tissue
and scores were determined for epithelial damage and inflammation. Colon tissue
cytokine gene expression levels were analyzed by RT-PCR. In study 1, DSS-induced
changes in BW, DAI and spleen weight were not increased by colon epithelial cellspecific VDR deletion (CAC; VDR KO). However, colon damage and inflammation at
10 day post DSS were still elevated in CAC; VDR KO mice compared to controls
although DSS induced expression of colonic NOS2, TNF-α and IL-1β mRNA were not
enhanced in those mice. The data indicates that VDR deletion in colon epithelial cells
protect against DSS-induced local tissue damage but does not affect the systemic
response. In study 2, DSS treated mice lacking VDR in non-epithelial cells (HV2; VDR
KO) had more severe BW loss, DAI and spleen enlargement than controls. Histologic

87
analysis showed that the HV2; VDR KO mice also had more severe colon damage and
inflammation than controls at day 10. DSS treatment induced colonic expression of Mɸassociated pro-inflammatory mediators (i.e. TNF-α, NOS2 and IL-1β) and this response
was significantly higher in the colon of HV2; VDR KO mice. These data suggest that
VDR deletion in Mɸs contributes to the robust pro-inflammatory response seen both in
the colon and systemically. The major finding of this work is that vitamin D-mediated
protection from experimental colitis is dependent upon VDR signaling in both colon
epithelial cells and in Mɸs, and the Mɸs are the primary vitamin D target cells during
colitis.

3.2

Introduction

Inflammatory bowel disease (IBD) refers to a chronic and relapsing inflammatory
response in the gastrointestinal tract, and it can be further categorized as Crohn’s Disease
(CD) or Ulcerative Colitis (UC) in humans (1). Even though the etiology of IBD is
complex and unclear, IBD disease risk is associated with multiple risk factors, including
genetics, life-style, infection, and immune system disturbance (2). All of these factors,
individually or combined, may affect the disease initiation, development, recovery and
relapse. Intestinal epithelial cells and immune cells play crucial but distinct roles in
maintaining intestine tissue homeostasis and preventing IBD development (3). Epithelial
cells form an intestinal barrier that prevents the infiltration of luminal bacteria and
foreign antigens into the body. Impaired barrier function (e.g. loosened tight junctions or
increased epithelial cell death) triggers a local immune response and induces chronic
inflammation in the gut (4, 5). Immune cells are needed to maintain immune tolerance,
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defend against infection and facilitate immune resolution and mucosa healing (6).
Disturbance of the biological functions in either cell compartment increases the risk of
IBD.
Vitamin D is a fat-soluble pre-hormone that can be absorbed from diet or be
synthesized in skin from 7-dehydrocholesterol under UV exposure (7). The biological
function of vitamin D is dependent on its active form, 1,25 dihydroxyvitamin D
(1,25(OH)2D), which binds to the vitamin D receptor (VDR) and regulates gene
transcription (8). 1,25(OH)2D has various biological functions, such as inducing calcium
absorption, modulating immune response and preventing cancer development (9).
Growing epidemiological evidence has shown that low vitamin D status is associated
with increased IBD risk, and that vitamin D supplementation significantly improved
human IBD outcomes (10-15). Similarly, in experimental colitis models low vitamin D
intake or VDR deletion caused more severe colon damage, inflammation and systemic
colitis disease activity in mice (16, 17). Moreover, human VDR polymorphism (i.e. ApaI,
BsmI, FokI and TaqI) is associated with both UC and CD risk (18-21). These results
indicate that vitamin D deficiency as a causal lifestyle factor in IBD development.
VDR is expressed in both intestinal epithelial cells and immune cells, and thus the
inhibitory effects of vitamin D on IBD may be through either or both of these cell
compartments. Previous studies showed that vitamin D signaling is crucial for
maintaining epithelial cell tight junction protein expression and localization, preventing
cytokine induced epithelial cell apoptosis, and inducing autophagy in Paneth cells; all of
which are related to intestinal epithelial cell mediated protection from colitis (22-24).
However, vitamin D also has anti-microbial and immune suppressive effects that in a
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diverse group of immune cells (25). Therefore in our study, we used two novel animal
models to test the independent role of VDR-dependent signaling in the two cell
compartments on DSS-induced colitis. Our data demonstrated that VDR in both colon
epithelial cells and non-epithelial cells (primarily immune cells) protects against DSSinduced colon tissue damage, but only VDR deletion in immune cells caused delayed
healing and more robust systemic colitis response.

3.3

Materials and Methods
3.3.1

Animals

CAC/DSS mice were generated and characterized by our laboratory (26, 27). This
mouse model has Cre-recombinase (Cre) transgene expression limited in colon, inducible
Cre transgene mediated recombination during DSS-colitis and sustained gene inactivation
during healing (26, 27). The novelty of the CAC/DSS mouse model made it suitable for
studying the role of a gene in colon epithelial cells during healing. Rosa26R, ApcCKO/CKO
and Vdrflox/flox were used to generate breeders in our experiments and they were all
previously described (26-28). HA-hVDR–Expressing Transgenic Mice (HV2Tg/-) express
an HA-tagged human VDR (hVDR) exclusively in the intestinal epithelium (29). Global
VDR knockout mice (VDR KO) were described elsewhere (30). All breeding colonies
were maintained on a C57Bl/6J background. They were housed individually, given a
standard chow diet and water ad libitum, and exposed to a 12-h light/12-h dark cycle in
the Life Science Animal Facility at Purdue. All mouse experiments were approved by the
Purdue Animal Care and Use Committee.
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In the pilot study and study 1, CACTg/-;Rosa26Rflox/-;ApcΔ580/WT (CAC) mice were
generated by breeding CACTg/-;Rosa26Rflo/flox and ApcCKO/CKO mice (27). Experimental
mice in study 1 with colon epithelial cell VDR inactivation,
CACTg/-;Rosa26Rflox/-;ApcΔ580/WT ;VdrΔex2/Δex2 (CAC; VDR KO) mice, were generated by
breeding CACTg/-;Rosa26Rflox/flox;VdrΔex2/Δex2 and ApcCKO/CKO ;Vdrflox/flox mice.
CACTg/-;Rosa26Rflox/flox;VdrΔex2/Δex2 mice were generated by first establishing a breeding
colony of Rosa26Rflox/flox;Vdrflox/flox double transgenic mice, then sequentially backcrossed
to CACTg/-;Rosa26Rflox/flox mice. ApcCKO/CKO;Vdrflox/flox mice were generated by sequential
backcrossing ApcCKO/CKO to Vdrflox/flox mice . In study 2, HV2Tg/- and VDR KO mice were
bred to generate experimental mice HV2Tg/-; VDR-/- (HV2; VDR KO). These mice had
VDR recovered in intestine but deleted from all other tissues including the entire immune
system. Control mice HV2Tg/- (HV2) were maintained by crossing HV2Tg/- with
C57BL6/J wild type mice. Genotypes were determined by analyzing tail genomic DNA
by standard PCR methods as previously described for CAC (26),Rosa26R (31), floxed
Apc allele (26), floxed VDR allele (28), HV2 (29) and VDR KO (32).
3.3.2

Study Design

Pilot study: Experimental mice (CAC) were weaned at 3 weeks of age and fed the
AIN93G diets containing either 1000 IU or 0 IU vitamin D3/kg supplement and deionized
water as libitum (n=112 per diet) (33). Mice in each diet group were randomly assigned
into one of four dextran sulfate sodium (DSS) treatment groups (0%, 0.65%, 1.35% and
2%, n=28 per dose balanced by gender). DSS (MW = 36,000-50,000 Da, MP
Biomedicals, LLC, Solon, OH)) was diluted in deionized water (w/v) to the appropriate
concentrations. At 8 weeks of age, mice received the DSS solution in place of water ad
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libitum for 5 consecutive days. Afterwards, DSS was replaced with deionized water and
this was provided until the day of sacrifice. Half of the mice in each group were
sacrificed 2 days after ending the DSS treatment and half were sacrificed 10 days after
ending DSS treatment. All mice were fasted overnight before harvest. Body weight
(BW), rectal bleeding and feces consistency of the mice were recorded daily from the
start of DSS treatment until the day of harvest. Spleen weight of each mouse was
recorded at the end of the study.
Study 1: 64 CAC (32 female and 32 male) and 64 CAC; VDR KO (32 female and 32
male) mice were weaned at 21 days old. All the experimental mice were fed standard
AIN93G diet containing 1000 IU vitamin D3/kg (33). Mice were treated with either
vehicle (0% DSS) or 1.35% DSS dose (n=64 per dose balanced by genotype and gender)
at 8 weeks old for 5 day, followed by deionized water until the harvest. Same as the pilot
study, mice were harvested at 2 day or 10 day after ending DSS treatment, and the BW,
rectal bleeding, feces consistency and spleen weight were measured in the same way. At
each harvest time point, tissue from half of the mice (n=8, balanced by gender, genotype
and DSS dose) were collected and preserved by formalin fixation, processed routinely,
and embedded in paraffin. Colonic tissues from these paraffin blocks were used for
histopathologic examination. Tissue from the other half of the animals (n=8) were harvest
for gene expression endpoints.
Study 2: 64 HV2 (32 female and 32 male) and 64 HV2; VDR KO (32 female and 32
male) mice were used in this study. The study design was the same as described in study
1.
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3.3.3

Live phase observation: daily BW loss and disease activity index

Mice were weighed daily from the start of DSS treatment (day -5) until the harvest
day. Mice rectal bleeding and feces consistency were also evaluated daily. Each mouse
was assigned a daily disease activity index (DAI) score as previously described by
Cooper et. al. (34). BW loss score is a 0-4 scale score describing the percentage of BW
loss daily (score 0= <1% loss from baseline; score 1= 1%-4.9% loss from baseline; score
2=5%-9.9% loss from baseline; score 3=10%-20% loss from baseline; score 4= >20%
loss from baseline). Rectal bleeding score is described by three values scaled from 0 to 4
(score 0= normal color feces; score 2= Feces are red to dark red-brown, but there is no
significant perianal blood staining or blood spots in the cage bedding; score 4= Perianal
blood staining and/or blood spots in the cage bedding). Feces consistency score is also
described by three values scaled from 0 to 4 (score 0= Normal formed feces; score 2=
Feces loosely formed a soft that do not stick to anus; score 4= Feces fail to form any type
of fecal pellet and/or there is perianal fecal staining). Daily DAI of each mouse was
calculated as the average value of the three individual scores.
3.3.4

Necropsy

Mice were fasted for approximately 12 hours before harvest. Mice were weighed and
then anesthetized with ketamine/xylazine (2 mg/g and 0.2 mg/g respectively). The blood
was collected by cardiac venipuncture. Spleen and large intestine were carefully dissected
and removed. The spleen was weighed and the colon length was measured. The colon
was cut open along its mesenteric border from the anus to the distal end of cecum. The
mucosa was carefully rinsed with cold phosphate buffered saline (PBS).
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3.3.5

Serum Metabolite Assays

Serum concentrations of 25(OH)D (n=16-19/group) and 1,25(OH)2D (n= 4-8/ group)
were determined as per the manufacturer’s instructions using radio immunoassays
(Immunodiagnostic Systems, Scottsdale, AZ). Total serum calcium (n=8-10/diet and DSS
group) was determined using a QuantiChrom Calcium Assay Kit (BioAssay Systems,
Hayward, CA) per the manufacturer’s instructions.
3.3.6

Formalin-Fixed Paraffin Embedded Tissue Collection

The colon was transected at its midpoint to separate the proximal and distal colon.
Each section was split longitudinally and Swiss-rolled (35), resulting in two rolls of
proximal colon and two rolls of distal colon per mouse. The spleen was cut along its
longest axis before fixation. Tissues were immersion fixed for 48 hours in 10% neutral
buffered formalin at 4°C before being transferred to 70% ethanol. Tissues were routinely
processed and embedded in paraffin within 7 days of collection at the Purdue Histology
and Phenotyping Laboratory.
3.3.7

Histology and Image Analysis

Colonic Swiss roll sections were cut at 4 µm thick and stained with hematoxylin and
eosin. The sections were blindly evaluated by FW under the supervision of a boardcertified veterinary pathologist (PWS). Quantitative morphology of colon was assessed
using ImageScope software (Aperio, Vista, CA). Scores were assigned to the distal colon
for extent of mucosal damage and immune cell infiltration. The criteria used for these
histologic component scores are summarized in Table 3.1.
Spleen samples were cut and stained using the same method as colon. Spleen H&E
stained images were taken from white light microscope (Leika, Germany) under an 8x
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eyepiece and a 4x objective. About 60% of total area was captured from each spleen
H&E stained sample. Spleen total area and white pulp area per image were measured
directly from Image J, while red pulp area was calculated by subtracting the white pulp
area from the total area. Percentage red pulp was calculated by dividing red pulp area by
the total area.
3.3.8

Gene expression

Colonic RNA was isolated from either whole colon tissue (Study 1) or a colonic
mucosa scraping (Study 2) using the Qiagen RNeasy kit. Spleen RNA was isolated using
Direct-zol RNA kits from Zymo research (catalogue No.R2050, Irvine, CA, USA).
Purified RNA was reverse transcribed to make cDNA and analyzed for TNF-α, NOS2
and IL-1β gene expression. The primer sets we used were pre-made by Integrated DNA
Technology (TNF-α Assay ID: Mm.PT.58.12575861; NOS2 Assay ID:
Mm.PT.56a.43705194; IL-1β Assay ID: Mm.PT.58.41616450).
3.3.9

Statistical analysis

Data was analyzed using SAS enterprise 5.1 software (SAS Institute, Cary, NC).
Histogram evaluation and Shapiro Wilk test of normality (p>0.05) were used to
determine if data were normally distributed. Percent BW loss, serum metabolites and
spleen weight were normally distributed and analyzed by 2-way ANOVA for the effects
of genotype, DSS doses, and their interaction. DAI, histologic scores, and spleen NOS2
gene expression were analyzed by Kruskal-Wallis non-parametric ANOVA for a main
effect of genotype. Colonic gene expression values were not normally distributed and
required log10 transformation prior to analysis by two-way ANOVA. Multiple
comparisons were done using Tukey adjustment. Spleen red pulp enlargement data was
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analyzed by student’s t-test. All data are reported as mean ± standard error of the mean
(SEM) and the differences were considered significant at p < 0.05 and trend at p<0.10.

3.4
3.4.1

Results

Low vitamin D intake resulted in deficient vitamin D status and more severe
colitis when treated with 0.65% or 1.35% DSS.

At the baseline, mice fed diet containing 1000 IU/kg vitamin D had an average
serum 25(OH) D level of 175.45 ± 11.80 nmol/L (n=16) compared to the low vitamin D
intake mice with an average serum 25(OH)D level of 16.86± 0.62 nmol/L (n=17).
Interestingly, 1.35% and 2% DSS treatment in vitamin D sufficient mice significantly
reduced the serum 25(OH)D level at 10 day after DSS termination (data not shown). The
low vitamin D intake resulted in deficient vitamin D status in mice without causing
hypocalcemia (serum calcium concentration =9.59 ± 0.29 mg/dL vs 10.87 ± 0.19 mg/dL
in low vs high vitamin D mice, n=18/group). Moreover, the baseline body weight of mice
with high or low vitamin D intake were not different (data not shown). DSS treatment
induced body weight (BW) loss in mice in a dose-dependent manner, while the mice with
low vitamin D intake had more robust response under 0.65% and 1.35% DSS treatment
(Figure 3.1). Spleen weight also increased after DSS treatment in a dose-dependent
manner. In the 1.35% DSS group, mice with deficient vitamin D status developed more
robust spleen enlargement compared to the ones with sufficient vitamin D (Figure 3.2).
Based on these results, the DSS dose in the following experiments was determined as
1.35%.
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3.4.2

Colon epithelial cell VDR deletion did not increase BW loss or DAI in mice after
DSS-induced colitis.

Mice with vehicle treatment had stable BW throughout the study, and no difference
in BW change at baseline was observed between CAC and CAC; VDR KO mice (data
not shown). DSS induced significant BW loss in both groups and the percentage of BW
loss in the two groups was similar (Fig 3.3A). DAI was significantly increased by DSS in
both CAC and CAC; VDR KO mice, reaching a peak value 2 days after stopping DSS
(Fig 3.3B). However, CAC; VDR KO mice did not develop more severe DAI compared
to CAC mice at either 2 or 10 d post-DSS (Fig 3.3B).

3.4.3

Non-epithelial cell VDR deletion increased DSS-induced BW loss and DAI.

Vehicle treated HV2 and HV2; VDR KO mice had stable and comparable BW
during the experiment (data not shown), while DSS treatment caused significant BW loss
in both groups (Fig 3.4A). HV2 mice had maximum BW loss of about 6% at 2 days after
stopping DSS, and BW recovered at day 5 after stopping DSS (Fig 3.4A). In comparison,
the HV2; VDR KO mice had more severe peak BW loss of greater than 10%, and their
BW failed to recover until the end of the study (Fig 3.4A). Significantly more severe BW
loss was observed in HV2; VDR KO mice from 4-8 days after DSS was removed
compared to the control mice (Fig 3.4A). In addition, DAI of HV2; VDR KO mice was
significantly higher than the controls from day -2 until the end of the study (Fig 3.4B).
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3.4.4

DSS-induced spleen enlargement was increased in mice with VDR deletion in
non-epithelial cells.

Spleen enlargement is often used as a systemic infection indicator and it is
commonly seen in DSS-induced colitis (17, 36). In study 1, both CAC and CAC; VDR
KO mice had increased spleen weight as a percentage of BW at day 10 after stopping
DSS, but no difference was seen between the two genotype groups (KO vs CAC = 0.49±
0.02% vs 0.52± 0.04%, n=16 vs 14 /group, p=0.71) (Fig 3.5A). In study 2, HV2; VDR
KO had significantly more severe spleen enlargement induced by DSS compared to the
HV2 controls (KO vs HV2 = 0.76± 0.04 % vs 0.52± 0.04 %, n=13/group, p<0.0001) (Fig
3.5B).

3.4.5

Mice with VDR deletion in both colon epithelial cells and non-epithelial cells had
more severe DSS-induced colon damage.

In study 1, DSS treatment caused colon mucosa damage in both CAC and CAC;
VDR KO groups, whereas CAC; VDR KO mice had more severe damage at both day 2
(p=0.0013 vs CAC) and day 10 (p=0.0283 vs CAC) after DSS termination (Fig 3.6A).
Similar results were observed in study 2 where HV2; VDR KO mice had more robust
colonic damage than HV2 mice at both time points (2 day, p=0.0794; 10 day, p=0.0155)
(Fig 3.6B). This suggests that VDR in both colon epithelial cells and non-epithelial cells
protects against DSS induced local tissue damage. Interestingly, CAC; VDR KO mice
had significantly reduced colon damage scores at day 10 compared to day 2 after DSS
was removed (p=0.0037) (Fig 3.6A), whereas colon mucosa damage of HV2; VDR KO
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mice was steady from day 2 to day 10 post DSS (Fig 3.6B). This suggests that loss of
VDR in non-epithelial cells delayed epithelial healing following DSS-induced colitis.

3.4.6

VDR deletion in both colon epithelial cells and non-epithelial cells caused more
severe immune cell infiltration in the colon.

DSS-treatment also increased colonic immune cell infiltration in mice. In study 1,
CAC; VDR KO mice had higher histological inflammation scores than controls at both
day 2 (p=0.0605 vs CAC) and day 10 (p=0.0036 vs CAC) after stopping DSS (Fig 3.7A).
Also, even though the colonic damage scores of CAC; VDR KO mice decreased with
time, the inflammation scores were sustained from day 2 to day 10 (Fig 3.7A). Similarly,
in study 2 HV2; VDR KO mice had significantly higher colon inflammation scores at day
10 than controls (p=0.0142), and did not decline from day 2 (2.13± 0.23) to day 10
(2.43±0.30) (Fig 3.7B).

3.4.7

Mice lacking VDR in the Non-epithelial cell compartment had a more severe
colonic Mɸ pro-inflammatory response.

Mɸ phenotypes are closely related to colon mucosa healing after DSS treatment,
with M1 being detrimental and M2 being beneficial (37, 38). We hypothesized that the
delayed colonic healing in HV2; VDR KO mice were caused by over-activated M1 Mɸ
response. To test this hypothesis, we examined the colonic M1 Mɸ cytokine profile in our
two studies. In study 1, NOS2 and IL-1β expression levels were slightly increased in the
colon of DSS treated mice, and TNF-α expression level returned to normal by 10 days
after DSS was removed. In contrast, the expression levels of the three genes in CAC;
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VDR KO mice were not statistically different from those in CAC controls (Fig 3.8A-C).
In study 2, TNF-α, NOS2 and IL-1β expression levels were significantly elevated by
DSS treatment and this response was significantly higher in HV2; VDR KO mice
compared to controls (Fig 3.8D-F). Since the three cytokines are predominantly produced
by pro-inflammatory Mɸs, the data indicate that local inflammatory Mɸ over-activation
is associated with increased colon mucosa damage and delayed healing seen in HV2;
VDR KO mice.

3.4.8

The enhanced systemic response to DSS-induced colitis in HV2; VDR KO mice
is due to over-activation of monocyte-Mɸ lineage in colitis.

All monocytes and a majority of Mɸs in the spleen are located in the red pulp, so we
first tested whether VDR deletion in the non-epithelial compartment enlarged the spleen
red pulp after DSS treatment. DSS treatment increased the red pulp by 20% in HV2 mice
at 10 d post DSS compared, In contrast, the DSS-induced enlargement of red pulp in
HV2; VDR KO mice was 45% and was significantly higher than that seen in HV2 control
mice (Fig 3.9A). We further analyzed the spleen Mɸ pro-inflammatory response by
measuring classically activated Mɸ marker NOS2 gene expression levels, and found that
HV2; VDR KO mice had a significantly higher NOS2 expression in spleen compared to
the controls (Fig 3.9B).

3.5

Discussion

Our pilot study independently confirmed that low dietary vitamin D intake caused
more robust DSS-induced BW loss and spleen enlargement in mice. The goal of the
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following two studies is to determine whether vitamin D signaling has an independent
role in colon epithelial cells and non-epithelial cells during colitis. We conducted two
experiments using mouse models with VDR deleted specifically from colon epithelial
cells or non-epithelial cells (primarily infiltrating immune cells), and found that vitamin
D signaling in both cell compartments protects against DSS-induced colon damage.
However, only deleting VDR from non-epithelial cells caused delayed mucosa healing
and more severe systemic colitis response. The increased colitis response was associated
with Mɸ over-activation in colon and systemically. Therefore, we conclude that an
important protective effect of vitamin D against colitis is through its regulation on Mɸ
response, while its protective role on colon epithelial cells is secondary.
Low vitamin D status is often diagnosed in human IBD patients, and mice with low
vitamin D intake or VDR deletion are more susceptible to developing experimental colitis
(16, 39-41). Lagishetty et al. found that mice with vitamin D deficiency developed more
severe BW loss and disease activity in DSS-colitis (41). This was consistent with a
previous report that mice with deleted VDR had increased mortality rate, more severe
BW loss and rectal bleeding in DSS-colitis (16). Moreover, these clinical symptoms of
DSS-induced colitis were significantly alleviated by rectal or intragastric administration
of 1,25(OH)2D in mice (16, 42). In our pilot study, we were able to independently
confirm that low vitamin D intake was the causal factor of more robust DSS-colitis in
mice, reflected by more robust BW loss and spleen enlargement. By using four different
doses of DSS, we found the most appropriate dose of 1.35% which was strong enough to
cause colitis but not too strong to mask the vitamin D effect in our mouse model.
Interestingly, Lagishetty et al. shown that 2.5% DSS reduced serum 25(OH)D levels in
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mice with high vitamin D intake but did not reach statistically significant. By increasing
the mouse number (n=8 vs 18/group), we observed a significant reduction of 25(OH)D
serum level at 10 d after stopping 1.35% and 2% DSS treatment. In the following two
studies, we observed the consistent results that non-epithelial cell VDR deletion in mice
resulted in more severe BW loss and DAI as seen in vitamin D deficiency. However,
these colitis symptoms were not observed in mice with VDR deleted from colon
epithelial cells. This suggests that vitamin D-mediated protection against colitis is
primarily through its regulation on non-epithelial cells, while blocking vitamin D
signaling in colon epithelial cells is not sufficient to cause more severe clinical response
in DSS-induced colitis.
Other studies showed that intestinal epithelial VDR protected mice from developing
DSS induced systemic colitis response, whereas our data suggested the opposite (24, 43).
This discrepancy can be explained by the different choices of animal models. For
example, previous studies used mice expressing villin promoter modified Crerecombinase, which deleted floxed VDR alleles from the entire intestine. Because VDR
in the small intestine is crucial for active calcium absorption, these mice develope
hypocalcemia when not fed a rescue diet (24, 43). Therefore, the robust colitis response
may also be due to altered calcium metabolism (24, 43). To avoid this issue, Liu et al.
then used an opposite model and investigated whether mice over-expressing intestinal
VDR (Tg or Tg-KO) would be resistant to DSS-induced colitis relative to wild-type mice
(WT) or VDR KO mice (KO) (23). They found that even through the mice expressing
human VDR transgene in the intestine developed less severe DSS-colitis clinical score
than WT, it only happened in the second round of DSS administration (each round=3%
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DSS 7d+ water 7d) (23). More importantly, Tg-KO mice still had higher colitis clinical
scores compared to Tg mice (23). This suggests that VDR in non-epithelial cells also has
a role in the response to colitis. This is in agreement with our results. To improve the
study design of previous studies, we used a DSS-inducible, large intestine specific
transgenic mouse model to test the contribution of colon epithelial cell VDR to DSScolitis prevention. This model ensured VDR inactivation in 40-50% colon crypts after
1.35% DSS administration, which was sufficient to inhibit VDR regulated vitamin D
signaling in damaged colon epithelium (23, 27). In addition, transgene induced VDR
inactivation was limited to the large intestine and thus would not interfere with body
calcium homeostasis or VDR regulated biological functions in other tissues (26, 27).
Based on our results, we conclude that colon epithelial cell VDR has impact on reducing
DSS-induced colon damage locally.
Vitamin D plays an important role in maintaining colonic barrier function,
potentially through maintaining epithelial cell permeability and autophagy, as well as
inhibiting cytokine induced epithelial cell apoptosis (22-24). Our results are consistent
with previous reports showing that deleting VDR from colon epithelial cells increased the
severity of colon epithelial damage and immune cell infiltration at both 2d and 10d after
ending 1.35% DSS treatment. Interestingly, a similar colonic response was also observed
in our HV2; VDR KO mice. This suggests that VDR-mediated signaling in both colon
epithelial cells and non-epithelial cells protects mice from developing colonic damage.
Even though deleting VDR from either colon epithelial cells or non-epithelial cells
caused more severe colonic damage in mice, delayed mucosa healing was only observed
in those with non-epithelial cell VDR deletion. Mucosa healing is a crucial IBD
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therapeutic goal; delayed healing extends the disease duration and therefore increases the
risk of IBD complications, such as colon cancer (44). Mucosa healing is a multi-step
process, including colon epithelial cell restitution, proliferation and crypt regeneration.
1,25(OH)2D (10 or 20 nM) was shown to induce Caco-2 cell migration in culture, and
prevent inflammation induced human HCT116 cell apoptosis; both of which may
facilitate mucosa healing after DSS-induced damage (22, 23). Previous animal studies
focused on the role of VDR on disease severity/mucosa damage using animals that were
sacrificed soon after experimental colitis was induced (16, 17, 40). To understand how
VDR in colon epithelial cells promotes mucosa healing we used our unique CAC/DSS
mouse model. In this model VDR deletion is limited to the site of epithelial damage (26,
27). By comparing the colonic damage score between 2 day and 10 day post DSS in
CAC; VDR KO mice, we found that the mucosa healing was not affected when removing
VDR from colon epithelial cells.
Mɸs, subtyped by M1 and M2, also affect the mucosa healing process (37, 38). Proinflammatory mediators (e.g. ROS and TNF-α) produced by M1 can induce colon
epithelial cell death and thus prevent healing, whereas other immune factors (e.g. IL-10
and TGF-β) produced by M2 may facilitate mucosa healing by suppressing local proinflammatory response and inducing epithelial cell growth (45-47). Previous research in
mouse models show that the M1/M2 Mɸ ratio increased during DSS administration and
decreased during mucosa healing (48, 49). Similarly, in humans, IBD patients treated
with infliximab or together with azathioprine (anti-TNF-α antibodies) had reduced total
Mɸ numbers (CD68+) and increased M2 Mɸ (CD206+) numbers in mucosa, followed by
improved mucosa healing (50, 51).
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Mɸs have long been known as a vitamin D regulating target (52, 53). 1,25(OH)2D
significantly suppressed M1 Mɸ cytokine production in culture after LPS induction and
in WT mice after DSS treatment (42, 54-58). Consistently, mice with global VDR
deletion developed more robust colonic inflammation and increased M1 Mɸ cytokine
levels (e.g. TNF-α, IL-1β and IL-12) when treated with DSS (16). Systemically, low
vitamin D intake caused more severe spleen enlargement in DSS-colitis, and this was
independently shown by Lagishetty et al. and us (17). Lagishetty et al. also demonstrated
that this increased spleen size was not due to increased T and B cell numbers or overactivated adaptive immune cytokine response (17). Therefore, we hypothesized that the
robust local and systemic response were mainly due to altered monocyte-Mɸ response. In
agreement with these previous reports, our data showed that only deleting VDR from
non-epithelial cells caused elevated colonic gene expression levels of M1 mediators
(TNF-α, IL-1β and NOS2) during mucosa healing. Moreover, these mice also had
significantly enlarged spleen red pulp (main location of monocytes and Mɸ) and M1
mediator NOS2 expression level in the spleen after DSS induced colitis. These data
suggest that altered Mɸ response is the primary cause of more robust systemic colitis and
delayed healing seen in vitamin D deficiency.

3.6

Conclusions

Our study has demonstrated that VDR-dependent signaling in both colon epithelial
cells and immune cells protects against mucosa damage, but only VDR in immune cells
protects mice from developing robust systemic response and delayed mucosa healing. We
further demonstrated that monocyte/Mɸ lineage is a significant target of vitamin D action
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during colitis. This suggests that the Mɸ is an important cell target for human IBD
prevention and that treatment with vitamin D or vitamin D analogs could be developed
reduce colitis. To further investigate the mechanism of how VD regulates monocyte/Mɸ
response in colitis, investigators need to ask 1) whether vitamin D signaling can directly
alter Mɸ phenotypes; 2) whether vitamin D regulates monocyte migration from bone
marrow or recruitment from circulation into colon tissue; and 3) whether vitamin D
regulates monocyte development in bone marrow during colitis. To confirm the role of
Mɸ VDR in experimental colitis, a lineage specific VDR deletion model needs to be used
to repeat the experiment discussed in this chapter. In the next chapter, I will mainly focus
on the first follow-up question mentioned above: can vitamin D directly regulate Mɸ
polarization and class switch in vitro?
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Table 3.1 Components of Histologic Grading Scheme for Colon Damage and
Inflammation
Score
0
1
2
3
4
Score
0
1
2
3
4
5

Colon Epithelial Damage Score
Description
No mucosal damage
1-25% of mucosa ulcerated or healing
26-50% of mucosa ulcerated or healing
51%-75% of mucosa ulcerated or healing
Greater than 75% of mucosa ulcerated or healing
Colon Inflammation Score
Description
No Inflammation
Mild increase in lamina propria leukocytes
Moderate increase in lamia propria and submucosal leukocytes
Submucosal edema and moderate to marked increase in lamina propria
and submucosal leukocytes
Extension of leukocytes into tunica muscularis and/or mild serositis
Extension of leukocytes through tunica muscularis with severe
serositis
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Figure 3.1 BW change of CAC mice fed high or low vitamin D diet during DSS-induced
colitis and recovery. (A) Daily BW change of mice treated without DSS. (B) Daily BW
change of mice treated with 0.65% DSS. (C) Daily BW change of mice treated with
1.35% DSS. (D) Daily BW change of mice treated with 2% DSS. (*, p<0.05; #, p<0.10).
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Figure 3.2 The average weight of the spleen as a percentage of BW in mice with high or
low vitamin D intake 10 day after stopping DSS. (*, p<0.05).
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Figure 3.3 BW change and disease activity index of CAC and CAC; VDR KO mice
during DSS induced colitis and recovery. (A) Daily BW change of mice treated with
1.35% DSS. (C) Daily disease activity index of mice treated with 1.35% DSS.
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Figure 3.4 BW change and disease activity index of HV2 and HV2; VDR KO mice
during DSS induced colitis and recovery. (A) Daily BW change of mice treated with
1.35% DSS. (C) Daily disease activity index of mice treated with 1.35% DSS (*, p<0.05,
#, p<0.10 vs HV2).
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Figure 3.5 The average weight of the spleen as a percentage of BW in mice 10 day after
stopping DSS. (A) CAC and CAC; VDR KO mice. (B) HV2 and HV2; VDR KO mice.
(Different letters, p<0.05).

116

A

CAC

CAC-VDR KO
&

^*

3.5
3.0
2.5

^*

2.0

^

1.5

^

1.0

HV2

HV2-VDR KO

4.0

0.5

Epithelail Damage Score

Epithelial Damage Score

4.0

B

N.S

^*

3.5

^#

3.0
2.5

^

2.0

^

1.5
1.0
0.5
0.0

0.0
NT

Day 2

Day Post DSS

Day 10

NT

Day 2

Day 10

Day Post DSS

Figure 3.6 . Colon epithelial damage score in mice treated with vehicle (NT) and
harvested at day 2 or day 10 post 1.35% DSS. Data represents histological score in distal
colon. (A) Epithelial damage score in the colon of CAC and CAC; VDR KO mice (^,
p<0.05 vs NT; *, p<0.05 vs CAC; &, p<0.05 vs Day 2). (B) Epithelial damage score in
the colon of HV2 and HV2; VDR KO mice. (^, p<0.05 vs NT; *, p<0.05, #, p<0.10 vs
HV2; N.S; not significant).
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Figure 3.7 Colon inflammation score in mice treated with vehicle (NT) and harvested 2
day or 10 day post 1.35% DSS. Data represents histological score in distal colon. (A)
Inflammation score in the colon of CAC and CAC; VDR KO mice (^, p<0.05 vs NT; *,
p<0.05, #, p<0.10 vs CAC; N.S; not significant). (B) Inflammation score in the colon of
HV2 and HV2; VDR KO mice. (^, p<0.05 vs NT; *, p<0.05 vs HV2; N.S; not
significant).
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Figure 3.8 Mɸ activation related gene expression levels in the colon of mice 10 day after
DSS was removed. Data represents gene expression in distal colon. TNF-α (A), NOS2
(B) and IL-1β (C) expression levels in the colon of CAC and CAC; VDR KO mice. TNFα (D), NOS2 (E) and IL-1β (F) expression levels in the colon of HV2 and HV2; VDR KO
mice. (Different letters, p<0.05).
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Figure 3.9 Spleen red pulp (RP) enlargement and Mɸ response at day 10 post DSS. (A)
Percentage spleen red pulp (RP) enlargement at day 10 post 1.35% DSS from the
baseline in HV2 and HV2; VDR KO mice. (B) NOS2 gene expression levels in spleen of
HV2 and HV2; VDR KO mice 10 day after DSS was removed. (*, p<0.05 vs HV2).
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4.1

Abstract

Macrophage (Mɸ) activation and phenotypes are closely related to the progression of
human inflammatory bowel disease (IBD). During colitis, classically activated Mɸs (M1)
produce pro-inflammatory mediators and induce colon tissue injury, while alternatively
activated Mɸs (M2) have anti-inflammatory features and facilitate colon mucosa
regeneration. Vitamin D is an immune modulator which may suppress colitis by
regulating Mɸ function, but the mechanism for this suppression is unknown. We tested
the hypothesis that 1,25 dihydroxyvitamin D (1,25(OH)2D) can directly induce M2 and
suppress M1 Mɸ activation and phenotype using murine peritoneal Mɸ culture. We
found that 1,25(OH)2D treatment alone or combined with IL-4 significantly induced
peritoneal Mɸs M2 marker Arg1 expression. 1,25(OH)2D also suppressed IFN-γ and LPS
induced M1 marker NOS2 expression by 20%. This suggests that 1,25(OH)2D can induce
polarization of Mɸs to the M2 subtype while inhibiting M1 Mɸ polarization in colitis.
Furthermore, we found that 1,25(OH)2D can regulate Mɸ phenotype switching by
shifting the balance toward M2 and away from M1. Taken together, our data
demonstrated that Mɸ phenotypes can be directly and significantly regulated by
1,25(OH)2D in vitro, even though the effect was not as strong as predicted. This finding
provides novel insight that vitamin D protects against colitis partially through regulating
Mɸ phenotypes onsite. Further studies are needed to investigate the regulation of vitamin
D on monocyte-Mɸ lineage at the stages prior to entering the inflamed colon, including
monocyte production, migration and differentiation during experimental colitis
progression.
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4.2

Introduction

Inflammatory bowel disease (IBD) is a condition of chronic and relapsing
inflammation in the gastrointestinal tract (1). Common symptoms of IBD include
increased and sustained immune cell infiltration and pro-inflammatory cytokine
production in the intestine (2). These chronic inflammatory responses cause intestinal
tissue damage and delayed mucosa healing, which then increases IBD severity and
duration (3, 4). Therefore, understanding the disease mechanisms and identifying
conditions that control the gut immune response could be a promising IBD prevention
and treatment strategy.
Macrophages (Mɸs) are crucial regulators of IBD development. Previous studies
reported that dextran sodium sulfate (DSS)-induced colitis significantly increases the
number of infiltrating Mɸs in the colon (5). However, Mɸs are a group of cells with high
heterogeneity, and their role in colitis is tightly related to these phenotypes and their
activation (6-8). Mature Mɸs can be polarized to two distinct phenotypes, M1 and M2,
depending on the presence of environmental cytokines or inducers (7-9). The two
phenotypes have distinct biological functions. M1 Mɸs produce pro-inflammatory
mediators (e.g. TNF-α and ROS), that stimulate adaptive immune responses and induce
tissue injury (10). In contrast, M2 Mɸs have anti-inflammatory features and facilitate
tissue healing (11). These cell functions are also relevant to the DSS-colitis model.
Following induction of colitis with DSS the ratio of M1 to M2 Mɸ increases to help
eliminate infiltrating bacteria. After removal of DSS, the ratio decreases coincident with
mucosal healing (12, 13). Therefore, manipulating Mɸ phenotypes during colitis may be
a novel IBD management strategy.
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Vitamin D is a crucial regulator of calcium absorption and bone health (14).
However, recent evidence shows that it has anti-inflammatory roles in multiple types of
immune cells including Mɸs, and in inflammatory diseases like IBD (15). Previous
research found that vitamin D receptor (VDR) knockout mice develop more severe DSSinduced acute colitis and that M1 Mɸs related-cytokine production (e.g. TNF-α, IL-1α,
IL-1β and IL-12) in the colon is increased. In addition, 1,25(OH)2D administration
reduces DSS-induced cytokine production in wild type mice (16, 17). In vitro studies also
showed that 24 hours pretreatment of 20 nM 1,25(OH)2D significantly suppresses LPSinduced pro-inflammatory cytokine production by mouse bone marrow derived Mɸs
(BMDMs). Similarly, Korf et al. observed that 48 hours pretreatment of 10 nM
1,25(OH)2D inhibited cytokine and chemokine gene expression of IFN-γ and LPS
induced murine peritoneal Mɸs (18, 19). However, it is not known whether 1,25(OH)2D
can influence M1 and M2 Mɸ polarization or regulate M1 and M2 Mɸ phenotype
switching when fully differentiated. In this study, we examined whether 1,25(OH)2D can
directly regulate Mɸ polarization and phenotype switch using cultured primary murine
peritoneal Mɸs.
4.3

Materials and Methods
4.3.1

Reagents

Mɸ culture medium was made of 45% RPMI 1640 (Sigma R0883), 45% high
glucose DMEM (GIBCO 11960), 10% FBS (Lonza), 100 U/ml Penicillin-streptomycin
(Invitrogen 15140-122), 2 mM L-glutamine (Life Technology 25030) and 20 ng/ml
murine M-CSF (R&D 416-ML-010). The culture medium was prepared within 1 week
before use and stored at 4oC.
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1α,25-Dihydroxyvitamin D3 (1,25(OH)2D) was purchased from Enzo Life Science.
1,25(OH)2D stock was prepared in pure ethanol to a concentration of 10-3 M and stored in
the dark at -80oC. 25x 1,25(OH)2D working stocks (2.5, 25 and 250 mM) were freshly
made by diluting 10-3 M 1,25(OH)2D into Mɸ culture medium right before use. Direct
light exposure to 1,25(OH)2D was avoided during the preparation.
Lipopolysaccharides (LPS) was purchased from Sigma (Catalogue# L4391). LPS
stock was prepared in RPMI 1640 supplemented with 10% FBS to a concentration of 1
mg/ml and stored at -80oC. 25x LPS working stock (25 ug/ml) was made by diluting 1
mg/ml LPS into Mɸ culture medium 1-7 days prior to use and stored at 4oC.
IFN-γ and IL-4 were purchased from Peprotech (Catalogue# AF-315-05 and AF214-14). The 20 μg/ml stocks of both cytokines were prepared in RPMI 1640
supplemented with 10% FBS and stored at -80oC. 25x working stocks (500 ng/ml) were
made by diluting 20 μg/ml cytokine stocks into Mɸ culture medium 1-7 days prior to use
and stored at 4oC.
4.3.2

Animals

C57BL6/J mice were purchased from The Jackson Laboratories and a breeding
colony was maintained in our lab. At weaning mice were group housed (4 mice/cage),
given a standard chow diet and water ad libitum, and exposed to a 12-hour light/12-hour
dark cycle in the Life Science Animal Facility at Purdue. All mouse experiments were
approved by the Purdue Animal Care and Use Committee.
4.3.3

Peritoneal cavity cell isolation and culture.

Peritoneal Mφs were harvested from 6-8 week old mice (male and female) and
cultured following published procedures with the following modification (20). Mice were
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sacrificed with CO2 and the peritoneal cavity cells were immediately collected by lavage
using 5 ml cold RPMI 1640 per mouse. Each mouse yielded 2-4 million peritoneal cells,
and the cells from 6-8 mice were pooled for each replicate of the experiments. Cells were
kept ice cold throughout the harvest.
Isolated peritoneal cavity cells were centrifuged at 4oC, 400 x g for 10 min and
suspended into Mɸ culture medium (500 μl/mouse) (20). 10 μl cell suspension was mixed
with an equal amount of 250 μg/ml trypan blue, and the viable cell number was
determined using a hemocytometer. Peritoneal cavity cells were diluted to a
concentration of 4 million/ml in the Mɸ culture medium. Cell suspensions were seeded
into each well on a 24-well (500 μl/well) or 48-well (250 μl/well) cell culture plate. After
2-4 hours incubation (37oC, 5% CO2), floating cells were removed with three washes of
RPMI 1640 (37oC). Flow cytometric analysis of the adherent cells showed that about
90% of the cells are F4/80 and CD11b double positive peritoneal Mɸs (M0) (20). The
purified Mɸs were allowed to rest for 1 hour before being treated to induce polarization.
4.3.4

Mɸ polarization and phenotype switching

In vitro Mɸ polarization was done following previously published procedures with
modification (20). Instead of treatment the cells with IFN-γ and LPS together, M1 Mɸs
polarization was induced by adding IFN-γ (final concentration: 20 ng/ml) for 1 hour
followed by 5 hours co-treatment of IFN-γ with LPS (final concentration: 1 ug/ml). M2
Mɸ polarization was induced by 6 hour treatment of IL-4 (final concentration: 20 ng/ml).
NOS2 and Arg1 gene expression levels were used to confirm M1 and M2 polarization,
respectively.
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To induce M1 Mɸ to switch to M2 Mɸ, polarized M1 Mɸ were washed 3 times with
RPMI 1640, afterwhich they were treated with Mɸ culture medium containing 20 ng/ml
IL-4. The gene expression ratio of Arg1 to NOS2 was measured to evaluate M1 to M2
phenotype switch. To induce M2 Mɸ to switch to M1 Mɸ, polarized M2 Mɸ were
washed 3 times with RPMI 1640, afterwhich they were treated with Mɸ culture medium
containing 20 ng/ml IFN-γ for 1 hour followed by 5 hour co-treatment of IFN-γ with
LPS. The gene expression ratio of NOS2 to Arg1 was measured to evaluate M2 to M1
phenotype switch.
To assess the impact of 1,25(OH)2D on Mɸ polarization and phenotype switching,
the following experiments are designed.
4.3.5

Experiments design

Experiment 1. Test the effect of 1,25(OH)2D alone on M0 polarization. M0
peritoneal Mɸs were cultured as described above. After washing off the floating cells,
500 μl Mɸ culture medium was added to each well on a 24-well cell culture plate. The
various final concentrations of 1,25(OH)2D (0, 0.1, 1 or 10 nM) were achieved by adding
10 μl culture medium or 25x 1,25(OH)2D working stocks with different concentrations.
After 6 hours incubation, cells were harvested for further analysis.
Experiment 2. Test the effect of 1,25(OH)2D on IFN-r and LPS induced M1
polarization. Mɸs were maintained as M0 or polarized to M1 as previous described. In
the M1 polarization groups, cells were co-treated with various concentrations of
1,25(OH)2D (0, 0.1, 1 or 10 nM) from the beginning of the polarization for 6 hours.
Experiment 3. Test the effect of 1,25(OH)2D on IL-4 induced M2 polarization.
Mɸs were maintained as M0 or polarized to M2 as previous described. In the M2
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polarization groups, cells were co-treated with various concentrations of 1,25(OH)2D (0,
0.1, 1 or 10 nM) from the beginning of the polarization for 6 hours.
Experiment 4. Test the effect of 1,25(OH)2D on M1 to M2 phenotype switch.
Mɸs were maintained as M0 or polarized to M1 as previous described. At the end of 6
hours polarization, two thirds of M1 polarized cells were washed with 37oC RPMI 1640
for three times. These cells were then incubated in Mɸ culture medium containing 20
ng/ml IL-4 with or without 10 nM 1,25(OH)2D for 6 hours. Cells were then harvested for
further analysis.
Experiment 5. Test the effect of 1,25(OH)2D on M2 to M1 phenotype switch.
Mɸs were maintained as M0 or polarized to M2 as previous described. At the end of 6
hours polarization, two thirds of M2 polarized cells were washed three times with 37oC
RPMI 1640. These cells were then incubated in Mɸ culture medium containing 20 ng/ml
IFN-r with or without 10 nM 1,25(OH)2D for 1 hour, and then co-treated with LPS for 5
hours to induce M1 class switch. Cells were then harvested for further analysis.
4.3.6

Mɸ harvest and gene expression analysis

Mɸs were washed three times with 37oC RPMI 1640 at the end of the experiments
and directly harvested into tri-reagent. Samples were collected in 1.5 ml screw cap tubes,
snap frozen in liquid nitrogen and stored at -80oC until use. RNA was isolated using
Direct-zol RNA kits from Zymo research (catalogue No.R2050, Irvine, CA, USA).
Purified RNA was reverse transcribed to make cDNA and analyzed for NOS2 and Arg1
gene expression; 18s ribosomal RNA (RNA18S) was used as a housekeeping gene. All
primer sets were pre-made by Integrated DNA Technology (Assay ID: RNA18S:
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Hs.PT.39a.22214856.g, NOS2: Mm.PT.58.43705194, Arg1: Mm.PT.58.8651372,
Coralville, Iowa).
4.3.7

Statistical analysis

Each experiment included 3-5 analytical replicates of the pooled sample and all
experiments were repeated at least three times. The data are expressed as the mean ±
standard deviation (SD) and were analyzed with SAS Enterprise 5.1. In experiments 1-3,
the gene expression levels of NOS2 and Arg-1 were normalized to the groups without
1,25(OH)2D treatment, and the differences among groups were analyzed by one-way
ANOVA followed by Fisher LSD multiple comparisons. In experiments 4 and 5, the
difference of gene expression or ratio between groups were analyzed by the student’s ttest. A difference was considered significant if the p value was less than 0.05.
4.4

Results

Arg1 marks the polarization of M2 Mɸ phenotype. Arg1 mRNA levels were
increased by 35% after 6 hours treatment with 1 nM 1,25(OH)2D (Figure 4.1), but higher
doses (10 nM) had no additional effect. This suggests that 1,25(OH)2D alone can induce
M2 Mɸ polarization.
M0 Mɸs had undetectable NOS2 expression. Treatment with IFN-γ and LPS
significantly elevated NOS2 mRNA levels (Figure 4.2), indicating that the M0 Mɸs were
successfully polarized to a M1-like phenotype. While 0.1 nM 1,25(OH)2D did not block
IFN-γ/LPS-induced NOS2 mRNA induction, high doses of 1,25(OH)2D treatment (1 and
10 nM) significantly suppressed induction of NOS2 mRNA by 20% (Figure 4.2).
Treatment of M0 Mɸs with IL-4 increased Arg1 mRNA level by 5.5 fold (Figure
4.3), indicating a successful induction of the M2-like polarization. Co-treatment of IL-4
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with 1,25(OH)2D significantly increased Arg1 gene expression by 30% only at the 10 nM
1,25(OH)2D dose (Figure 4.3).
Incubating M1-like Mɸs with 20 ng/ml IL-4 for 6 hours significantly reduced NOS2
mRNA level and increased Arg1 mRNA level (Figure 4.4 A-B) leading to an increased
Arg1/NOS2 gene expression ratio, indicating a successful induction of the M1-to-M2phenotype switch (Figure 4.4 C). Co-treatment of 10 nM 1,25(OH)2D with IL-4 further
reduced NOS2 expression levels by 20% but did not alter Arg1 mRNA levels (Figure 4.4
A-B). This suggests that 1,25(OH)2D may only have a mild effect on inducing M1-to-M2
phenotype switch (Figure 4.4 C).
IFN-γ and LPS treatment significantly increased NOS2 and reduced Arg1 mRNA
levels in M2-like Mɸs (Figure 4.5 A-B), resulting in a significant increase of the
NOS2/Arg1 mRNA ratio (Figure 4.5 C). This indicated a successful induction of M2 to
M1-like Mɸ phenotype switch. Co-treatment with 10 nM 1,25(OH)2D significantly
reduced NOS2 mRNA levels, but did not significantly increase Arg1 mRNA levels
(Figure 4.5 A-B). 1,25(OH)2D reduced the NOS2/Arg1 mRNA ratio by 40% (Figure 4.5
C), indicating a moderate inhibitory effect of 1,25(OH)2D on the M2-to-M1 phenotype
switch.
4.5

Discussion

Here we conducted a series of experiments using primary mouse peritoneal Mɸ
models and confirmed that Mɸ phenotypes are directly regulated by 1,25(OH)2D.
Specifically, 1,25(OH)2D suppressed expression of the M1-like Mɸ marker NOS2 but
induced expression of the M2-like cell marker Arg-1. This suggests that 1,25(OH)2D can
inhibit M1 polarization and facilitate M2 polarization. Consistent with this conclusion,
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1,25(OH)2D can also inhibit the M2-to-M1 phenotype switch and induce M1 to polarize
to M2 Mɸ with mild to moderate effects.
Studying the mechanism of 1,25(OH)2D regulation on Mɸ polarization and
phenotype switching has a significant implications for the management of human IBD.
As what has been discussed in previous chapters, low vitamin D status is often diagnosed
in human IBD patients, and mice with low vitamin D intake or VDR deletion are more
susceptible to developing experimental colitis (16, 21-23). Vitamin D has been proposed
to have anti-colitis effects while its regulating targets -Mɸs- are proved to play a central
role in experimental colitis and human IBD progression (12, 13). Froicu et al. showed
that mice with global VDR deletion developed more robust colonic inflammation and had
increased M1 Mɸ cytokine levels (e.g. TNF-α, IL-1β and IL-12) when treated with DSS,
but the mice were not fed rescue diet so the effect caused by VDR KO may also be due to
altered calcium metabolism (16). By recovering VDR in the intestine using HV2; VDR
KO mice (chapter 3), our study excluded the co-factor of calcium and independently
confirmed that the M1 Mɸ cytokine levels were significantly elevated in HV2; VDR KO
mice, and that this increase was associated with delayed mucosa healing after DSS
induced colon damage. The elevated M1 response in inflamed colon may be due to
increased total Mɸ number in the colon, or due to altered Mɸ phenotype. It has been long
considered that the Mɸ infiltrating number in the gastrointestinal tract indicates the
disease stage, because increased pro-inflammatory Mɸs numbers were observed in the
colon of both DSS-colitis and human IBD (5, 24). However, this viewpoint has been
challenged as the Mɸ phenotypes and functions are linked to IBD progression. During
gut inflammation, circulating monocytes are recruited to the intestine and further
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differentiate into either classically activated Mɸ (M1) or alternatively activated Mɸ (M2),
depending on the environmental cytokine profiles (10, 25). M1 Mɸs are polarized by LPS
and IFN-γ and characterized as pro-inflammatory Mɸs. They produce large amounts of
pro-inflammatory mediators (TNF-α, IL-1, IL-12 and ROS) to stimulate local immune
response and induce tissue damage (10). M2 Mɸs are anti-inflammatory Mɸs induced by
IL-4 or IL-13 (25). Unlike M1, M2 cells produce high levels of IL-10 and growth factors
(e.g. TGF-β) to inhibit M1 activity and facilitate mucosa healing (11). Collectively, M1
Mɸs are believed to be detrimental in colitis especially during mucosa healing, while M2
Mɸs have a protective effect during the disease progression (12, 13). Therefore, it is
essential to demonstrate the contribution of vitamin D on Mɸ phenotype regulation and I
hypothesize that the increased M1 response seen in HV2; VDR KO mice colon is due to
unbalanced M1 and M2 Mɸ phenotype.
Early evidence showed that 50 nM 1,25(OH)2D can induce bone marrow derived
Mɸ differentiation with increased cell surface expression of M2 marker mannose receptor
after 2-4 days culture (26). Later on, 1,25(OH)2D (10 nM, 3 days) was used to
differentiate M2-like cells from the human monocyte cell line THP-1 (27). Unfortunately,
these studies were conducted either before the concept of M2 Mɸ coming into place or
without sufficient details about cell polarization due to different research goals (vitamin
D and monocyte to Mɸ differentiation). Therefore, the question of whether vitamin D can
directly regulate M2 Mɸ polarization still requires further investigation. Our study
independently showed that 1,25(OH)2D alone significantly induced M2 marker Arg1
gene expression level in peritoneal steady stage Mɸs, but the mechanism for this effect is
unknown. In vitro M2 Mɸ polarization requires IL-4 to activate the JAK-STAT6
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pathway, which then induces Arg1 expression (28). In the EAE mouse model of multiple
sclerosis, vitamin D increases Th cell STAT6 gene expression and enhances Th2
polarization (29). Since STAT6 is also expressed in Mɸs and drives IL-4 induced M2
polarization, we hypothesize that 1,25(OH)2D can induce M2 polarization by regulating
the same pathway(30). Our results showed that 1,25(OH)2D increased IL-4 induced Arg1
expression in M2-like Mɸ, which was consistent with our hypothesis. However, further
experiments are required to determine whether STAT6 is a direct 1,25(OH)2D target gene
or whether JAK-STAT6 signaling is affected in Mɸs by 1,25(OH)2D.
1,25(OH)2D is an immune modulator which can suppress Mɸ pro-inflammatory
response. 1,25(OH)2D suppresses a variety of pro-inflammatory cytokines in human
monocyte/Mɸs cell lines (31-33), and a similar immune-suppressive effect was also seen
in mouse Mɸ cell lines (e.g. P388D1) and primary cell cultures (e.g. BMDM and
peritoneal Mɸ) (18, 19, 34). For example, Korf et al. showed that 48 hours pretreatment
of 10 nM 1,25(OH)2D significantly inhibited IFN-γ and LPS induced M1 gene expression
levels (e.g. NOS2 and TNF-α) of mouse peritoneal Mɸs (18, 19). In addition, 24 hours
co-treatment of 1,25(OH)2D suppressed IFN-γ induced oxidative burst and host defense
mediators in murine BMDMs (35). Mechanistically, 1,25(OH)2D was found to suppress
NF-κb and MAPK/AP-1 pathways to inhibit Mɸ pro-inflammatory response (18, 19, 28,
34, 36, 37). For example, Cohen-Lahav et al. demonstrated that pre-incubation with 100
nM 1,25(OH)2D significantly reduced LPS stimulated TNF-α production from mouse Mɸ
cell line P388D1 by prolonging Iκbα-mRNA half-life and by decreasing Iκbα
phosphorylation (34). This may also explain the inhibition of p65 nucleus translocation
by 1,25(OH)2D (34). 10 nM 1,25(OH)2D significantly inhibited LPS-induced IL-6 and
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TNF-α production by human monocytes and mouse BMDM with increased MAPK
phosphatase-1 level, while the 1,25(OH)2D effect was significantly reduced when using
BMDM from MAPK phosphatase-1 knockout mice to repeat the experiment (36, 37). To
fit within the concept of Mɸ polarization, our study showed that 6 hours 1,25(OH)2D
treatment was sufficient to inhibit IFN-γ and LPS induced M1 Mɸ polarization by
suppressing Mɸs NOS2 expression levels.
Other studies have demonstrated that M1 and M2 phenotypes can be stimulated to
switch phenotypes (9, 38), and this has been independently confirmed in our study. In
DSS-induced experimental colitis mouse model, the ratio of M1 to M2 Mɸ number
increased with colitis severity, while the ratio decreased during disease recovery and
mucosa healing (12, 13). Similarly, in humans, IBD patients treated with infliximab or
together with azathioprine (anti-TNF-α antibodies) had reduced total Mɸ numbers
(CD68+) and increased M2 Mɸ (CD206+) numbers in mucosa that was followed by
improved mucosa healing (39, 40). A recent study using RAW 264.7 cell line showed
that 1,25(OH)2D significantly induced high glucose stimulated M1-like Mɸ s to classswitch to a M2 phenotype; this effect is mediated through upregulating the PPARγ
signaling pathway (41). Our study used IFN-γ and LPS as M1 stimuli, and independently
showed that 1,25(OH)2D significantly suppressed IL-4 polarized M2 Mɸs to switch to a
M1 phenotype. By changing the M1 stimuli in the culture system, our study may better
mimic the impact of 1,25(OH)2D on Mɸ phenotype switching in the microenvironment of
inflamed colon induced by DSS.
Even though the regulation of Mɸ phenotypes by 1,25(OH)2D has been
demonstrated here in vitro, whether this is also the scenario in colitis mouse models with
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vitamin D signaling deficiency remains unknown. Future studies need to address this
question to emphasize its clinical implication. Moreover, the modulating effect of
1,25(OH)2D is much milder than that of the M1 or M2 Mɸ polarization inducers.
Compared to the dramatic effect of immune cell VDR deletion caused severe colitis
described in the previous chapter, the 1,25(OH)2D-induced mild to moderate local Mɸ
polarization regulation is not sufficient to explain the observation in vivo. Further studies
also need to determine the effect of vitamin D signaling in monocyte generation,
migration and monocyte to Mɸ differentiation during colitis.

4.6

Conclusions

The current study demonstrated that 1,25(OH)2D can suppress M1 Mɸ polarization
while facilitating M2 Mɸ polarization. Meanwhile, we also found that 1,25(OH)2D has a
significant impact on inhibiting M2 to M1 class switch in vitro. Taken together, our
findings contribute to the understanding of the colonic protective effect of vitamin D in
IBD and provide novel insights into IBD management. These results may also shed light
on other diseases with inflammation caused tissue injury.
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Figure 4.1 Arg1 gene expression levels in steady M0 peritoneal macrophages treated with
different doses of 1,25(OH)2D. Data was normalized to 0 nM 1,25(OH)2D treatment
group. (1,25D, 1,25(OH)2D; Different letters, p<0.05).
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Figure 4.2 NOS2 expression levels in peritoneal M0 or M1 Mɸs treated with different
doses of 1,25(OH)2D. Data was normalized to 0 nM 1,25(OH)2D treated M1 polarization
group. (1,25D, 1,25(OH)2D; Different letters, p<0.05).
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Figure 4.3 Arg1 expression levels in peritoneal M0 or M2 Mɸs treated with different
doses of 1,25(OH)2D. Data was normalized to 0 nM 1,25(OH)2D treated M2 polarization
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Figure 4.4 Gene expression levels of NOS2 and Arg1 during Mɸ M1 to M2 phenotype
switching in the presence or absence of 1,25(OH)2D. NOS2 gene expression (A), Arg1
gene expression (B) and Arg1/NOS2 expression ratios of peritoneal Mɸs with different
treatment. M0, non-polarized peritoneal Mɸs. M1, IFN-γ and LPS polarized peritoneal
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switch. NOS2 and Arg1 expression levels were normalized to M1-M2 group. Arg1/NOS2
gene expression ratios were calculated from raw data. (D, 1,25(OH)2D *, p<0.05; #,
p<0.10).
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CHAPTER 5.

RESEARCH SUMMARY AND FUTURE DIRECTIONS

5.1

Research Summary

My thesis work aimed to achieve two major research goals. The first was to develop
a mouse model for studying the colon epithelial cell gene function in colitis, and the
second was to investigate the cell targets and mechanisms of vitamin D-mediated
protection against colitis. Here I will summarize the main findings regarding these two
goals, as detailed in the previous chapters.
The study reported in chapter 2 described a novel mouse model for colitis and
colitis-associated colon cancer research. The utility of this model was originally reported
in 2010 and then was expanded by several means (1, 2). First, the Cre-mediated transgene
induced gene recombination was not only restricted in the large intestine, but also
expanded after DSS treatment. This allowed us to test the gene function in colon
epithelial cells during colitis without confounding factors from other tissues. Second, this
expansion was strongly correlated with epithelial damage and was sustained during and
after the epithelial healing. This made it possible to measure the gene function
specifically in mucosa healing. Even though the mechanism of the reported phenomena is
unknown, we hypothesized that the colonic stem cells are affected because of the
involvement of crypt base cells and their long lasting effect. Stem cell lineage tracing is
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required to further identify the contribution of a specific group of stem cells to mucosa
healing and their transgene activity during DSS induced colitis in mice.
With the promising model developed, we then investigated the effect of colon
epithelial cell VDR on DSS-induced colitis prevention. We found that even though colon
epithelial cell VDR deletion resulted in more severe colon damage induced by DSS, it
was not sufficient to cause delayed mucosa healing, increased colonic cytokine
expression or more robust systemic colitis response. On the other hand, non-epithelial
cell VDR KO mice recaptured all the local and systemic colitis symptoms seen in vitamin
D deficiency and VDR KO, including increased colonic damage and inflammation,
delayed healing, more robust body weight loss, spleen enlargement and DAI. Therefore,
we conclude that colon epithelial cell VDR is not sufficient to prevent colitis
development or maintain mucosa healing.
Next I investigated the mechanism of non-epithelial cell VDR deletion that caused
delayed mucosa healing and severe colitis. I specifically asked the question of whether
monocyte-Mɸ lineage is the primary vitamin D regulating target. Three lines of evidence
support this hypothesis. First, in the colon tissue of mice with non-epithelial cell VDR
deleted, pro-inflammatory Mɸ cytokine expression levels were significantly elevated
during the mucosa healing stage after DSS treatment. However, this was not seen in the
colon epithelial cell VDR KO mice. Second, Mɸ marker NOS2 was significantly induced
in the spleen of non-epithelial cell VDR KO mice but not in colon epithelial cell VDR
KO mice. Third, spleen red pulp, where monocytes and most Mɸs are located, was
significantly enlarged in non-epithelial cell VDR KO mice. These data suggest that
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vitamin D mediated monocyte-Mɸ lineage response strongly affects DSS-induced
experimental colitis in mice.
Figure 5.1 summarizes this cell lineage response during experimental colitis and
potential vitamin D regulating steps, including monocyte differentiation in bone marrow,
emigration to blood circulation, migration to colon, Mɸ polarization in inflamed colon
and their interaction with T cells. I first hypothesized that vitamin D can directly
modulate Mɸ polarization and phenotype switch away from M1 and towards M2 in the
colon during colitis. This hypothesis was partially supported by the experiments I
performed in chapter 4 using primary Mɸ culture. I found that 1,25(OH)2D treatment
significantly suppressed M0 to M1 polarization and M2 to M1 phenotype switching in
the pro-inflammatory environment, and this also fit with the observation in HV2; VDR
KO mice that deleting VDR from immune cells elevated M1 response. 1,25(OH)2D also
induced M2 polarization in the presence or absence of IL-4. Even though 1,25(OH)2D
modulates Mɸs phenotypes, it is much less effective than the cytokine inducers.
Moreover, the effect seen in cell culture experiments (Chapter 4) was much less dramatic
than that in the colon of HV2; VDR KO mice (chapter 3). Therefore, I hypothesize that
other mechanisms may still exist to contribute to the colitis response seen in HV2; VDR
KO mice, including the upstream regulation on monocyte migration.

5.2

Future Directions

Previous experiments reported in this thesis mainly focused on potential vitamin D
mediated Mɸ polarization and activation in the colon tissue, but the increased M1 Mɸ
response in the inflamed colon seen in HVV2; VDR KO mice may also be due to
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upstream regulation in blood circulation and in bone. To further investigate the
mechanism of vitamin D mediated protection from colitis through monocytes and Mɸs
requires the following questions to be answered.

Question 1: Does Vitamin D signaling prevent monocyte migration from blood
circulation into the inflamed colon?
Rationale: Mɸs in the inflamed colon are differentiated from blood monocytes after
their migration to the tissue (3). The monocyte migration process is strongly dependent
on the MCP-1/CCR2 pathway (3). MCP-1 is produced by multiple cell types in the colon
when it is infected, including blood vessel endothelial cells, colon epithelial cells, stromal
cells and others (4). Among these cell types, Mɸs are the most significant producers of
MCP-1(4). CCR2 is expressed on the cell surface of monocytes, which receives the
MCP-1 signaling and induces the migration event. Vitamin D signaling may inhibit
monocyte migration to local tissue by reducing colonic MCP-1. Evidence showed that
colonic MCP-1 expression was increased in mice with DSS induced colitis, and further
elevated in mice with intestinal VDR deletion (5, 6). In AOM/DSS induced colon cancer
mouse model, VDR deletion increased both the tumor burden in the colon and the MCP-1
expression level in the tumor (7). In vitro, LPS induced MCP-1 production by THP-1
cells and THP-1 induced Mɸs, and this pro-inflammatory effect was significantly
suppressed by 1,25(OH)2D pre-treatment in both groups of cells (8). This suggests that
1,25(OH)2D may directly regulate monocyte-Mɸ MCP-1 expression and thus induce
monocyte migration to the inflamed colon.
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Hypothesis: vitamin D signaling inhibits monocyte migration from blood circulation
to inflamed colon by suppressing MCP-1 production in DSS-colitis mice.
Experiments: In our experiments discussed in chapter 3, the increased Mɸ proinflammatory response in HV2; VDR KO mouse colon may be due to elevated colonic
MCP-1 level and total Mɸ number. To test the hypothesis, MCP-1 gene expression levels
in both CAC; VDR KO and HV2; VDR KO mice should be measured and I expect to see
increased MCP-1 only in HV2; VDR KO mice colon. Total Mɸ numbers in the colon of
HV2; VDR KO and control mice should be measured by immunohistochemical staining
of CD68. I expect to see increased Mɸ numbers in the colon of HV2; VDR KO mice.
Furthermore, the direct regulation of 1,25(OH)2D on monocyte migration in vitro should
be tested using transwell culture system.

Question 2: Can vitamin D signaling suppress monocyte emigration ability from bone
marrow during colitis?
Rationale: Systemic inflammation induces bone marrow monocyte production and
emigration and thus increases circulating monocyte numbers. Monocyte emigration from
bone marrow is also dependent on the MCP-1/CCR2 pathway (9). As mentioned before,
monocytes express high levels of CCR2 on the cell surface and monocytes CCR2
deletion caused their accumulation in the bone marrow after LPS injection in mice (9).
Vitamin D was proposed to have anti-migration effects partially through its suppression
of CCR2 expression on monocytes/ Mɸs (6, 10). MCP-1 is the chemokine ligand of
CCR2 which is mainly produced by monocytes in the blood (4). At steady stage, serum
MCP-1 ensures that newly differentiated monocytes emigrate into the circulation and
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replenish the blood monocyte population. This MCP-1 level was elevated in mice fed
western diet containing low vitamin D and calcium (11). Serum MCP-1 concentration is
positively correlated with circulating CD11b+ monocyte numbers in mice (12) and is
upregulated in both DSS and TNBS induced experimental colitis model in mice (5, 13).
However, whether low vitamin D signaling induces serum MCP-1 levels or monocyte
emigration from bone marrow to blood circulation remains unknown.
Hypothesis: vitamin D signaling inhibits MCP-1 induced monocytes emigration
from bone marrow to blood circulation during DSS-colitis.
Experiments: First I will test the serum MCP-1 concentration in HV2; VDR KO
and control mice with DSS-colitis in chapter3, and I expect to see that the MCP-1 serum
levels are high in HV2; VDR KO mice. I also want to test the total blood monocyte
(Ly6C+CD11b+) numbers in HV2; VDR KO mice and expect to see elevated numbers
compared to controls. Since blood monocytes are the major source of serum MCP-1, I
will also measure the MCP-1 production in vitro from LPS stimulated murine monocytes
with or without 1,25(OH)2D, and I expect to see reduced monocyte MCP-1 production
with 1,25(OH)2D treatment.

Question 3: Does VDR in monocytes and Mɸs protect mice from experimental colitis?
Rationale: Several lines of evidence showed that monocytes and Mɸs are the
essential immune regulators during colitis. As described in chapter 1, systemic infection
increased bone marrow monocyte production and Mɸ phenotype balance was tightly
related to DSS-colitis progression and recovery (14, 15). In addition, T cell mediated
colitis in mice can be alleviated by transferring M2 Mɸs into the peritoneum (16). Since
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vitamin D can potentially regulate monocyte-Mɸ biology at different stages, I
hypothesize that VDR in monocyte –Mɸ lineage has a protective role in colitis
development. To test this hypothesis, one needs to induce colitis in a mouse model with
monocyte-Mɸ VDR deletion. Currently, three mouse models have been developed to
study myeloid cell biology with Cre recombinase expressing in monocytes and Mɸs (17).
The first model is LysMCre. LysMCre mouse model has Cre transgene expression in the
myeloid cell lineage, including monocytes and mature Mɸs, but also granulocytes (e.g.
neutrophils) (18). Therefore the gene function observed from this model will have a
confounding effect from neutrophils. The second model is Cx3cr1-cre or Cx3cr1-creER
(19). These mice have transgene expression in most of the tissue resident Mɸs, but these
resident Mɸs are not our main focus in DSS-colitis. The third model is FVB-Tg(Csf1ricre)1Jwp/J (cfms-icre) (20). CSF-1 signaling is crucial for monocyte lineage
development in bone marrow and Csf1r is expressed in different stages of monocyte
precursors. Using cfms-icre to inactivate VDR will cause confounding effects from
dendritic cells and bone marrow derived granulocytes derived from those precursors. To
overcome the non-specificity, an inducible model Tg(Csf1r-Mer-iCre-Mer)1Jwp was
developed to limit the recombination event in blood monocytes (21) . The disadvantage
of this model is that the Cre transgene activation requires daily injection of 4hydroxytamoxifen which increases the complexity and variation of the experiments (22).
Given these considerations, we will use the LysMCre model for future experiments.
Hypothesis: VDR signaling in monocyte-Mɸ lineage protects against DSS induced
colitis in mice.
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Experiments: Mice with monocyte-Mɸ lineage VDR deletion (LysMCre-VDR KO)
can be generated by crossing LysMCre with VDRΔex2/Δex2 breeders. DSS-colitis will be
induced as described in chapter 3. I hypothesize that LysMCre-VDR KO mice will
develop more severe systemic and colonic response in DSS-colitis. I expect to see that
LysMCre-VDR KO mice have 1) more severe body weight loss, DAI and spleen
enlargement; 2) increased serum MCP-1 concentration and Ly6C+CD11b+ cell number in
the circulation; and 3) increased total Mɸ number and elevated ratio of M1 to M2 Mɸ cell
number/response in the colon.

Question 4: Is MCP-1 a direct VDR target gene?
Rationale: Previous research showed that 0.2 μg/ml LPS induced MCP-1 production
in THP-1 cells can be significantly suppressed by 24-48 hours treatment of 100 nM
1,25(OH)2D (8). More interestingly, 4 hours 1,25(OH)2D treatment was sufficient to
suppress THP-1 cell MCP-1 gene expression by over 50% without LPS stimulation (23).
This quick response suggested a direct regulation of 1,25(OH)2D on MCP-1 gene. To
investigate whether MCP-1 is a vitamin D target gene in THP-1 cells, the authors also did
FAIRE-seq, VDR ChIP-seq and CTCF ChIP-seq and found the overlapping regions
among the analysis (23). This suggests that VDR can directly regulate MCP-1 gene
transcription but further experiments are needed to identify the functional VDREs. Since
mouse models are widely used to study human colitis, it is also crucial to determine
whether MCP-1 is a direct regulating target in primary mouse monocyte-Mɸ lineage. It is
also important to identify potential murine and human functional VDREs in MCP-1 gene
promoter and enhancer regions to make further comparisons across the two species.
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Hypothesis: MCP-1 is a vitamin D target gene.
Experiments: First I need to confirm that 1,25(OH)2D treatment can also suppress
MCP-1 gene expression in murine monocytes and Mɸs with or without LPS stimulation.
Next I will do bioinformatics analysis to identify putative VDRE sequences in the MCP-1
promoter and enhancer regions. The ENCODE project portal
(http://genome.ucsc.edu/ENCODE/) will be used to identify DNase I hypersensitive sites
(HSS) in the MCP-1 mouse gene. Putative VDREs within these HHS will be identified
with Lasagna-Search 2.0. EMSA and Chromatin immunoprecipitation (ChIP) assay will
then be performed to test the binding capacity of VDR to the identified putative VDREs.
If the binding capacity of VDR for these putative VDREs is demonstrated in the promoter
region, a reporter gene assay will be used to test the function of these VDREs. If the
putative VDREs are identified in the enhancer regions, a Chromatin Conformation
Capture experiment will be used to test the function of the VDREs.
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Figure 5.1 Monocyte-Mɸ lineage response during experimental colitis and potential
vitamin D regulating targets. Bone marrow: monocytes are differentiated from bone
marrow. This process is M-CSF dependent and potentially upregulated by vitamin D.
Monocyte emigration from bone marrow to blood circulation is MCP-1/CCR2 dependent
and this is potentially inhibited by vitamin D. Blood: monocytes circulating in blood
produce increased level of MCP-1 during DSS-colitis, which induced the cell emigration
from bone marrow to blood. Blood monocytes also migrate to inflamed colon and this
process is also regulated by MCP-1/CCR2 signaling. Colon: migrated monocytes will
differentiate into M1 or M2 Mɸs depending on the cytokine profile in the colon
microenvironment. The differentiated M1 or M2 Mɸ phenotypes are also interchangeable.
Colonic Mɸs can also interact with T cells during colitis.
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